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ABSTRACT 
 
Serum samples were obtained from 350 animals comprising of 302 sheep and 48 
goats with signs of brucellosis from different localities in West Bank, Palestine. 
None of the animals were vaccinated against Brucella. These samples were 
subjected to serological examination for the detection of specific brucella 
antibodies. The percentage of the positive brucellosis sera was found to be as 
follows: 31% in sheep sera and 52% in goats sera by Rose Bengal test (RBT), 
giving overall seroprevalence of 34%. The overall seropositivity using 
Complement Fixation Test (CFT) was 31%; 29% in sheep sera and 44% in goats 
sera.  Eighty milk samples collected from seropositive animals were subjected to 
bacteriological examination. Brucella organisms were detected in 38 (47.5%) of 
the samples. Testing the milk samples by polymerase chain reaction (PCR), all the 
38 positive samples detected by bacterial examination were also detected by PCR. 
Furthermore, with the PCR, we were able to additionally detect 24 (30%) infected 
milk samples that were negative by the bacterial isolation method. B. melitensis 
was identified from 42 out of 80 milk samples. The hemagglutinin gene sequence 
of two of the B. melitensis genes was PCR-amplified using the primers ORF and 
IS711, sequenced and subsequently aligned with other GenBank-accessible gene 
sequences of B. melitensis and other Brucellae spp. using version 2.0 of BLAST. 
These sequences were identical to that of the recent sequence of type strain of B. 
melitensis (ATCC 23456).  Nucleotide comparison and restriction enzyme analysis 
of hemagglutinin revealed that the two current isolates were different from vaccine 
(Rev.1).  The results of phylogenetic analysis revealed that they  
xiv 
 
were genetically close to the isolates from different Mediterranean countries, 
particularly those from France, Spain and Israel. 
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  الملخص
تشخيص ودراسة  جرثومة البروسيلا في الأغنام والمعز المتواجدة في منطقة الضفة 
  تقانات الأحياء الجزيئية الغربية، فلسطين بواسطة
ھدف الدراسة ھو الكشف عن نسبة تواجد اضداد جرثومة البروسيلا في الأغنام والمعز المتواجدة في منطقة 
 )TBR(الضفة الغربية، فلسطين التي ظھرت عليھا أعراض داء البروسيلا باستخدام اختباري وردية البنكال 
كانت نسبة .  من الماعز 84و  من الأغنام 803عينة مصل  053إذ تم جمع .  )TFC(واختبار تثبيت المتمم 
على التوالي %( 25، %13)تواجد أضداد جرثومة البروسيلا باستخدام وردية البنكال في الأغنام والماعز 
، %92)في حين بلغت نسبتھا  استخدام اختبار تثبيت المتمم  في الأغنام والماعز %( 43)وبنسبة كلية بلغت 
عينة من الحليب من الأغنام أو  08إضافة إلى ذلك ُجمعت %(.  13)وعلى التوالي وبنسبة كلية بلغت %( 44
كانت نسبة .  المعز التي أظھرت تواجد اضداد جرثومة البروسيلا بغرض زراعة وعزل جرثومة البروسيلا
  عينة حليب  08من أصل %( 5.24) 43الحصول على مزارع لجرثومة البروسيلا 
بواسطة بادئات التفاعل النوعية الخاصة بكل نوع من  )RCP( استعمل فحص تفاعل البلمرة المتسلسل النوعي
 26تم الكشف عن وجود جرثومة البروسيلا في .  لفحص عينات الحليب 117SIالبروسيلا للعنصر الوراثي 
وكذلك أشارت نتائج تفاعل البلمرة بواسطة البادئات النوعية (.  08)من مجموع عينات الحليب %( 77)عينة 
  .عزلة  24البروسيلا المالطيه وجود  الخاصة بجرثومة
لعزلتين من البروسيلا  )ninitulggameH(تم دراسة تسلسل الحامض النووي المركب لجين مقترحة ھو 
باستخدام نظام ( 1 veRالعترة )المالطية من العينات الحقلية وتم مقارنتھا مع سلالة لقاح البروسيلا المالطية 
بالرغم من . حيث كان تشابه بين ھاتين العزلتين وسلالة لقاح البروسيلا LCLCالتوافق الموجود في برنامج 
أظھر اختلاف واضح في طريقة  III eaHھذا التشابه الأ ان ھضم الجينن المفترض باستخدام الأنزيم القاطع 
  .الھضم بين السلأتين التي تم دراستھما و سلألة اللقاح 
مفترض للعزلين السابقين مع جينات مفترضة مشابھة للجينات اظھرت مقارنة تسلسل الحمض النووي للجين ال
المشخصة للبروسيلا من حيث التسلسل والتي تم البحث عنھا في شبكة المعلومات بواسطة الشجرة الجينية أن 
   .ھاتين العزلين أقرب لعزلات البروسيلا المالطية المعزولة في فرنسا، إسبانيا وإسرائيل
  :أثبتت الدراسة
مما يدل على أنه لا .  )TFC(واختبار تثبيت المتمم  )TBR(جود توافق بين اختياري وردية البنكال عدم و. 1
  .يمكن الاعتماد على اختبار واحد في الكشف عن تواجد اضداد جراثيم البروسيلا كإختبار مسحي وتشخيصي
ة مميزة لعينات البروسيلأ تشخيصي أن استخدامات الحمض النووي المطور ذات فعالية عالية و سرعة كأداة.  2
 ھذه التقانات له مستقبل واعد كمصدر فعال في استخدام. المعزولة من الحقل مقارنة بطرق التشخيص التقليدية 
  . إنتاج القاحات الجزيئية
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بين عزلأت البروسيلأ المالطية في فلسطين وسلالة لقاح البروسيلا   أظھرت الدراسة اختلاف واضح. 3
  ( 1 veRالعترة )المالطية 
أظھرت الدراسة ان عزلأت البروسيلأ المالطية في فلسطين  أقرب لعزلات البروسيلا المالطية المعزولة في . 4
  . فرنسا، إسبانيا وإسرائيل  من ناحية وراثية
للقطيع باستخدام سلالة  لمرض في الحيوان وذلك بإتباع سياسة التطعيم الكلىتوصي الدراسة بالسيطرة على ا
لقاح البروسيلا المالطية ذات العلأقة القريبة للعزلأت في فلسطين أولا ثم تبني سياسة تنفيذ برامج إرشادية 
لدراسات كما توصي الدراسة أيضا إجراء مزيد من ا. البروسيلا للأناس الأكثر عرضة لخطر الإصابة بمرض
  .القطر لمعرفة لمزيد عن وبائية المرض على نطاق واسع تشمل كل
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                                                                      CHAPTER I 
INTRODUCTION 
 
Brucellosis has great health significance and economic importance in many 
countries worldwide. Brucella melitensis, a gram negative bacterium, is the 
leading cause of brucellosis in sheep and goats, and the most important causative 
agent of brucellosis in humans. Infections in animals caused by Brucella spp. 
frequently result in abortions and diminished levels of milk production. Once the 
acute period of the disease is over, animals may present little or no disease 
symptoms, and Brucella cells can chronically be located in the supramammary 
lymphatic nodes and mammary glands of 80% of infected animals; thus, animals 
continue to secrete the pathogen in their body fluids. Transmission to humans 
occurs upon consumption of contaminated raw milk and contaminated dairy 
products.  Therefore, there is no doubt that control of this disease in animals will 
have an immediate impact on the incidence rate of this disease in humans (1, 2). 
Brucellosis is an ancient disease with a low mortality rate, which causes a 
substantial residual disability in man. Human brucellosis remains the major 
bacterial zoonosis in the world with devastating economic effects on the 
productivity of livestock. Humans, who become incidentally infected due to 
contact with infected animals or ingestion of dairy products, may develop 
numerous symptoms. Disease frequently becomes chronic and may relapse, even 
with treatment (3). In cattle, sheep and goats, the initial phase after infection is 
often not apparent. In sexually mature animals, the Infection is localized in the 
reproductive system and typically results in placentitis followed by abortion in 
pregnant females during the last  two months of pregnancy, and epididymitis and 
orchitis in males (4). 
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Keeping the mentioned facts about brucellosis in mind, the present study was to 
examine serum and milk of 350 animals (302 sheep and 48 goats) obtained from 
different localities in the West Bank, Palestine:  
1. To study the seroprevalence of brucellosis in sheep and goats by detecting 
antibodies in serum employing RBT and comparing it with CFT. 
2. Isolation and identification of Brucella from milk and confirmation by 
molecular methods. 
3. Genetical characterization of representative isolates of B. melitensis related to 
the vaccine strain used here and some isolates from different Mediterranean 
countries 
 
1.1 Epidemiology of Brucellosis 
Brucellosis is distributed worldwide and is recognized as a zoonosis of great 
economic importance. In developed countries, certain human infection is 
associated 
with meat-packing and dairy-related occupations. Brucellosis is transmitted 
among  
animals through the gastrointestinal tract, skin and mucus membranes. The 
organism reaches the lymph nodes and bacteremia occurs. Brucella then 
proliferates in the uterus and in the mammary glands. Growth in the chorionic 
membranes of the pregnant animal leads to abortion (5). 
Brucella spp. are named for their primary host and subdivided into biovars based 
on serologic agglutination with “smooth lipopolysaccharide (S-LPS) – associated”  
antigens M and A. B. melitensis infect sheep and goats. It may also be found in 
cattle due to indirect contact with infected sheep and goat flocks sharing 
contaminated pastures. B. melitensis is divided into 3 biovars: biovar 1, 2, 3. B. 
abortus is pathogenic to cattle, but can also infect sheep, goats, canines, horses 
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and humans. The species comprises 7 biovars (1-6, and 9,  biovars 7 and 8 are no 
longer valid). B. suis contains 5 biovars: biovars 1, 2 and 3 are found in swine, 
while biovar 4 is found in reindeer and caribou in the Arctic regions of North 
America and Russia, and biovar 5 infects rodents. B. canis strains comprise a 
single biovar that infect dogs in U.S., Mexico, Argentina, Spain, China, Japan and 
Tunisia. B.ovis and B. neotomae each contain a single biovar and are found in 
rams and wood rats. B. melitensis, B. abortus and B. suis are associated with 
human disease, with B. melitensis the most virulent species. B. canis rarely causes 
infection in humans (6).  
Brucellosis is distributed throughout areas of both the eastern and western 
hemispheres. Indigenous animal and human infections occur in the Mediterranean 
region, the Arabian gulf, the Indian subcontinent, Latin America, Asia and parts 
of  
Mexico. B. abortus distribited worldwide while B. suis is endemic in the southern 
U.S., Southeast Asia and Latin America. Caprine and ovine brucellosis are no 
longer detected in Northern Europe, Denmark and Norway. This is due to 
successful control and eradication programs. Southern European regions are still 
infected with B. melitensis in animals and humans. Brucellosis is a big problem in 
the Balkan region of Central and Southern Europe. B. abortus is found in Greece 
and Macedonia. The countries with the highest incidence of both animals and 
human brucellosis are  
 
Palestine, Saudi Arabia, Iran, Syria, Jordan and Oman. B. melitensis biovar 3 is  
common in Egypt, Israel, Tunisia, Turkey, and Jordan. Brucella melitesis biovar 2, 
is common is present in Saudi Arabia, and Turkey while biovar 1 is found in 
Libya, Oman, and Israel (7). 
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1.2 Brucellosis in Palestine. 
In Palestine, human brucellosis has been reported annually since 1987 with a peak 
in 1990. In order to encourage people to report this disease, the Ministry of Health 
offers free treatment to the population. However, under-diagnosis and 
underreporting of cases is a recognized problem in this country. It is estimated 
that for each reported case there are at least two additional cases that are not 
reported and not diagnosed. Therefore, the actual number of cases may be 
approximately three times as many as the reported number. Irrespective of how 
one enumerates cases, it is clear that brucellosis has become endemic in the 
human population in Palestine. Evidence suggests that it is also enzootic in 
animals, especially sheep and goats, with prevalence in these animals of 
approximately 5% to 6% in some Palestinian districts.  
The environment in the West Bank and Gaza is favorable for the spread of 
brucellosis,  
but incidence rate is less than expected. Reasons for this lower incidence rates can 
be explained by the underreporting of cases, limited intensive animal breeding and 
poor economic circumstances resulting in low consumption of milk, milk products 
and meat. In addition, closure of the border by the Israeli authorities, has resulted 
in drastically reducing lower the number of infected animals purchased from 
Bedouins  
 
and farmers residing in Israel. The condition of closed border applies to other  
neighboring countries such as Jordan, Egypt, Syria and Lebanon (8).  The 
incidence rate of brucellosis in humans is approximately equal in all age groups, 
suggesting that all age groups are at risk. In Palestine care for animals is carried 
out mainly by women and this explains higher incidence rates in females. 
Consumption of milk, dairy products and cheese in particular, constitutes the 
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major risk factor for transmission among people living in urban areas. 
Consumption of unpasteurized sour milk is the major risk factor of transmission 
among people living in refugee camps. Other risk factors for brucellosis may 
include eating uncooked vegetables contaminated with excreta of infected animals 
and inhalation of dust contaminated by it. A high proportion of cases occurs 
during the spring and summer seasons.  In spring, the delivery season, 
transmission occurs by consumption of unpasteurized milk or dairy products as 
well as direct animal contact during delivery of infected flock.  In the summer 
season, transmission is due to increased consumption of milk and cheese. 
Consumption of insufficiently cooked or undercooked meat of goats, sheep and 
cattle with brucellosis in general, and  bone marrow, liver and spleen of small 
ruminants in the bacteremic stage in particular, may also be a source of infection.   
Brucellosis is a professional hazard where groups of people engaged in handling 
live infected goats and sheep or their products are continuously at risk of 
brucellosis. Such groups include shepherds, animal caretakers and handlers, 
veterinarians, slaughterhouse workers, sheep-shearers and laboratory workers who 
can become infected while handling materials contaminated with Brucella spp (8)  
or during vaccinating the 
 
animals if the safety rules are not followed correctly( 9 ).  
 
Years No of infected 
people 
1998 837 
1999 747 
2000 304 
2001 273 
2002 166 
2003 267 
2004 153 
2005 115 
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Table 1.2.1: Repeated cases of human Brucellosis from period 1998 to 2008 in 
the West Bank (Brucellosis project)(10). 
 
The vaccination of sheep and goats with live Brucella melitensis Rev1 strain 
vaccine may cause abortion. But this live vaccine is recommended by 
international organization - Office International Epizooties (OIE) and directorate 
of veterinary services and animals health to use for conjunctival vaccination all 
sheep and goats in Palestine. Instructions dictate that this vaccine should not be 
applied to pregnant animals. Occasionally, sometimes farmers and veterinarians 
are unaware of the pregnancies (first or second month of pregnancy) thus animals 
receiving the vaccine with the consequence of abortion. This holds the Palestinian 
government responsible. Differentiation in the Central Veterinary Laboratory 
between circulating wild strain and Rev 1vaccine strain would eliminate 
ambiguities concerning the real cause of abortion in animals. 
 
1.3 Control of Brucellosis in Palestine 
Before 1994 the veterinary service in Occupied Palestinian Territories (OPT) was 
under authority Israel Civil Administration. Since 1974 were implemented 
vaccination strategies and in 1981 reports the result of analyses of blood samples 
2006 79 
2007 206 
2008 198 
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and aborted material in suspected cases of brucellosis. The aim of OPT was to 
reduce or minimize the incidence of infection in animals and human. Since 1982 
have been vaccinated only young female sheep and goats (two-seven month old) 
with Rev 1 subcutaneous full dose. Vaccination has been compulsory and free 
charge. In 1992, the OPT veterinary service initiated a partial test and slaughter 
policy if mean: testing vaccinated animals (those with their ears notched have 
been vaccinated) after their first delivery (when the animals are 18 month of age 
and older), testing unvaccinated animals older than 8 month. In June 1992, in the 
Hebron area, (when one third of the total sheep and goat population of the West 
Bank is considered), the Israeli Veterinary Department began collecting blood 
samples and testing them with Rose Bengal and Complement Fixation test. In 
1993, the Israel paid compensation for each infected animals and impounded the 
meat NIS250-300 per animals. Since the initiation of this policy, 200 animals 
were slaughtered. 
In 1997 start Palestinian Brucellosis Control Project. This project was funded by 
the Spanish Cooperation and implemented by the United Nations Development 
Program  
(UNDP) in Cooperation with the Palestinian Ministry of Agriculture through the 
Directorate of Veterinary Services and Animal Health. The project aims to 
contribute to significant reduction of the cases and incidence of Brucellosis in 
small ruminants, predominantly sheep and goats, as well as humans in the West 
Bank, Gaza and East Jerusalem. In addition,   efforts are being made by the 
Palestinian Brucellosis Control Program (PCBP) to control Brucellosis as 
recommended by international organizations (FAO, OIE and WHO). These efforts 
will result in drastic reduction in the prevalence of Brucellosis in animals to a 
minimum through conjunctival mass vaccination, which will reflect in lowering 
the number of human cases. The project also intends to implement new policies to 
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improve proper diagnosis of brucellosis by veterinarians, develops surveillance 
and monitoring programs, and to enhances public awareness and eventually 
eradicates this disease 
Within this project public awareness campaign was developed and directed toward 
educating the public about the menace of brucellosis.  This campaign promoted 
the production and broadcasting of three documentaries about brucellosis, and two 
TV comedies, with participation and education of students from schools 
particularly those in hot areas such as Hebron and Dura (10).  
 
               1.4 Decrease of animal Brucellosis during Brucellosis project 
The effect of the brucellosis project in Palestine in reducing the number of cases 
in   animals and flocks are shown in Tables 2, 3, 4. The drastic reduction in 
brucellosis in the year 2005 (Table 3) as compared to the year 1998 (Table 2) is 
clearly evident. The  
number of areas and percent positive for both animals and flocks in the year 2009 
is shown in Table 4. We can conclude that the effort of this project were fruitful in 
most cities and areas in the West Bank. Hopefully, with continued effort, we 
expect to see  very low incidence rates (2% international standard) 
 
 
               Table 1.4.1: The prevalence of Brucellosis between animals in 1998 in West 
Bank 
(10) 
 
 
 
 
 
District 
%+ve by RBT 
2005 
%+ve by flock 
2005 
Hebron 5.1 53 
Bethlehem 6.9 84 
Jerusalem 4.7 47 
By animals By flocks 
18% 75% 
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Jericho 4.9 47 
Ramallah 8.2 67 
Salfit 7.9 45 
Nablus 4.9 35 
Tulkarem 3.8 25 
Qualquilia 6.8 55 
Tubas 3 35 
Jenin 5.6 35 
Total 5.8 48 
                
 
                     Table 1.4.2: The prevalence of Brucellosis between animals in 2005 by RBT 
(10) 
 
 
 
District Result by flocks 2009 Result by animals 2009 
No No 
+ve 
by 
RB
T  
% 
+ve 
by 
RB
T 
No 
+ve 
by 
CF
T 
% 
+ve 
by 
CF
T 
No No 
+ve 
by 
RB
T 
% 
+ve 
by 
RB
T 
No 
+ve 
by 
CF
T 
% 
+ve 
by 
CF
T 
Dura 14 8 57 6 42 233 18 7.7 12 5.2 
Hebron 37 29 78 25 68 824 56 6.8 44 5 
Bethlehem 29 7 24 6 21 360 8 2.2 6 1.7 
Jerusalem 34 7 21 7 21 1004 8 1 7 0.8 
Jericho 49 24 49 21 43 1694 109 6.4 57 3.4 
Ramallah 36 15 42 10 28 1117 23 2.1 14 1.3 
Salfit 17 4 24 3 18 218 5 2.3 4 1.8 
Nablus 57 23 40 20 35 1137 96 8.4 76 6.7 
Tulkarem 32 5 16 4 13 451 8 1.8 7 1.6 
Qualquilia 5 6 40 4 27 189 10 5.3 7 3.7 
Tubas 32 16 50 4 4 829 73 8.8 57 6.9 
Jenin 47 14 30 14 30 749 34 4.5 26 3.5 
Total 418 159 38 133 32 8851 483 5 345 3.7 
 
Table 1.4.3:  The prevalence of Brucellosis in 2009 by district in West Bank by 
RBT and CFT (10). 
 
1.5 Human- to Human Transmission: 
Human to human transmission is rare. Infections with Brucella can be 
transmitted via blood transfusion and bone marrow transplantation from infected 
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donor (11). Neonatal infection can be acquired by the transplacental route, during 
delivery or via the ingestion of contaminated breast milk during breast feeding 
(12, 13). 
 
1.6 Brucella species 
Brucellae are gram-negative coccobacilli (short rods) measuring about 0.6 to 1.5 
µm. They are non-spore forming organisms that lack capsule and non flagellated, 
therefore non-motile. The outer cell membrane closely resembles that of other 
Gram-negative bacilli with a dominant lipopolysaccharide (LPS) component and 
three main groups of proteins. The metabolism of the Brucellae is mainly 
oxidative and they show little action on carbohydrates in conventional media. 
They are aerobes, but some species require an atmosphere with added 5-10% 
CO2. Multiplication is slow at the optimum temperature of 37οC and enriched 
medium is needed to support adequate growth. Brucella colonies become visible 
on suitable solid media in 2-3 days. The colonies of smooth strains are small, 
round and convex but dissociation, with loss of the O chains of the LPS, occurs 
readily to form rough or mucoid variants. Rough or mucoid variants are natural 
in B. canis and B. ovis since the LPS of these organisms lack the O chains (14). 
Brucella melitensis is found in sheep, goats and humans, but may be found in 
cattle sharing contaminated pastures.  
 
1.7 Molecular characteristic of Brucella spp 
Brucellae spp. are closely related with percent relatedness of 96 ± 4% between 
species. An insertion element IS711 is common in all species, but may be located 
on different sites on the bacterial chromosome depending on the species. 
Variations among different Brucella species are found on the lipopolysaccharide 
(LPS) and outer membrane proteins (OMP) (16). A recent study (17) proposed 
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that all Brucellae species belong to a single species, Brucella melitensis, and all 
other species should be regarded as biovars of Brucella melitensis (Brucella 
melitensis biovar melitensis, abortus, suis, canis).  Molecular genetic studies and 
restriction endonuclease mapping revealed gene polymorphism that can 
differentiate between B.abortus, B.melitensis, B.suis, and B.canis (17). One of the 
polymorphic genes that help differentiate the various Brucella species is omp 2 
porin gene which encodes for a 36-kDa OMP which is responsible for 
susceptibility to the dyes used for conventional species identification (12). 
Brucella species have two chromosomes except B.suis biovar which has a single 
chromosome. The genome of Brucella melitensis strain 16M was sequenced and 
found to contain 3,294,931 base pairs distributed over two circular chromosomes 
of 2,117,144 bp and 1,177,787 bps (12). Each chromosome encodes functions 
that are essential for replication and survival of the organism. Endogenous 
plasmids, transformation and conjugation have not been described in Brucella 
species (17). 
1.8 Virulence Factors and Pathogenecity of Brucella melitensis 
 Brucella melitensis is an intracellular pathogen that can survive and multiply 
within phagocytic cells of the host. The mechanism by which B. melitensis 
evades intracellular killing is not fully elucidated. Nevertheless, Brucella 
organisms ultimately become sequestered within monocytes and macrophages of 
the reticuloendothelial system (RES) in lymph nodes, liver, spleen and bone 
marrow (16). Although humoral antibodies appear to play some role in resistance 
to infection, the principal mechanism of recovery from brucellosis is cell-
mediated. Cellular immunity involves the development of specific cytotoxic T 
lymphocytes and activation of macrophages, enhancing their bactericidal activity, 
through the release  
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of cytokines (e.g. gamma interferon and tumor necrosis factor) from specifically 
committed helper T lymphocytes. Coincident with the development of cell-
mediated immunity, the host usually demonstrates delayed type hypersensitivity 
to Brucella antigens (12, 16). 
At the molecular level, antigenic variation is the result of decreased expression of 
genes encoding the additional glycosylation of the polysaccharide moieties of the 
cell wall lipopolysaccharide (LPS). Organisms that are in the smooth phase 
posses a smooth-type LPS (S-LPS) and are resistant to intracellular killing by 
polymorphonuclear cells (PMNs), presumably by inhibiting lysosomal 
degranulation and the respiratory burst associated with PMN activation. After its 
entrance in the host, the monocytic-macrophagic system is the target for the 
pathogen, where it is able not only to survive, but also replicate. The pathogen 
evades host defence by inhibiting endsome fusion with lysome and may reach the 
endoplasmic reticulum (18). The markers for biovar determination, also have a 
role in organism virulence, as monoclonal antibodies directed against the S-LPS 
are protective in animal challenge models, and smooth isolates that have lost S-
LPS by transposon mutagenesis have attenuated pathogenicity for mice. The S-
LPS O (somatic antigen) chain from smooth B. melitensis and smooth B. abortus 
strain are both composed of polymers of 4,6-dideoxy-4-formamido-D-mannose 
(N-formyl-D-perosamine). In B. melitensis O chain, α 1,2 and α 1,3 linkages 
occur in a 4:1 ratio (M determinants). The serodominant A antigen tends to be 
rod-shaped, the shape being determined by  
the five consecutive α 1,2-linked residues, whereas the serodominant M antigen 
is  
“kinked” in shape because the fourth residue is linked to the fifth by an α 1,3 
linkage. The common expression of nonterminal α 1,2-linked N-formyl-D-
perosamine is responsible for the cross-reactivity see between S-LPS of smooth 
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B. abortus and smooth B. melitensis strains and the cross-reactivity that is seen 
with other species (16). 
 
1.9 The characteristics of a variant strain of Brucella melitensis Rev 1. 
The Rev.1 vaccine was developed in the 1950s by a two-step selection involving 
firstly streptomycin resistance and dependence and secondly reversion of 
dependence but keeping streptomycin resistance. The evidence is presented for 
the  
occurrence of a variant of a vaccine strain of B. melitensis Rev 1, designated 
"FSA" (foreign South African). FSA resembles Rev 1 in its reactions to penicillin 
and streptomycin but reacts closer to a field strain of B. melitensis with regards to 
the dyes (thionine and basic fuchsin) sensitivity and colony size. Colonies of Rev 
1 were consistently smaller than other B. melitensis strains, their size 0,75 mm as 
opposed to the 1-2 mm, while B. melitensis 16M colonies were 1,25-1,5 mm. Rev 
1 was found to be urease positive, unless a test of low sensitivity was applied.(19, 
20). The live attenuated strain B. melitensis Rev.1 is considered the best vaccine 
available for the prophylaxis of brucellosis in sheep and goats. (20). 
Chromosomally acquired streptomycin resistance is frequently due to mutations 
in the gene encoding the ribosomal protein S12, rpsL. Nucleotide sequencing 
revealed one mutation in the rpsL gene of vaccine strain Rev.1 compared to that 
of reference strain 16 M leading  
to an amino acid Pro-to-Leu change at codon position 91 (Pro91Leu). This 
mutation resulted also in the lack of a NciI restriction site in the gene. PCR-
restriction fragment length polymorphism (PCR-RFLP) using NciI applied to a 
large number of Brucella reference and field strains showed that the mutation 
detected was specific of vaccine strain Rev.1 (21). 
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1.10 Laboratory Diagnosis of Brucella melitensis 
It is extremely important to follow safety rules when handling specimens for 
cultivation of Brucella which poses significant hazard to clinical laboratory 
personnel. The diagnosis of brucellosis in the laboratory is primarily based on 
serology. Rose Bengal test is commonly performed for screening. If positive, 
subsequent Complement fixation test (CFT) and saline agglutination test (SAT) 
are performed.  Culture for brucellosis is rarely needed to diagnose human 
infections (22, 16).  
Culture for B. melitensis is usually done for blood and body fluid samples. Blood 
cultures should be incubated for total of 21 days. Blind subcultures should be 
made every 7 days before reporting the culture as negative (23). Rapid detection 
methods of Brucella in clinical samples are considered to be optimal for the 
identification of infections caused by this organism. Polymerase chain reaction 
(PCR), enzyme-linked immunosorbent assays (ELISA) and immunofluorescent 
staining are usually used for rapid detection.  PCR is primarily used to detect B. 
melitensis directly in the milk of suspected animals. In addition, this highly 
sensitive and specific technique can be performed on vaginal swabs obtained 
from animals who ercentlyhad abortion (24,25,26,27).  
 
1.11 Clinical manifestations of Brucellosis in humans. 
1.11.1 Osteoarticular complications 
Bone and joint involvement are the most frequent complications of brucellosis, 
occurring in up to 40% of cases. Patients usually present with fever and back 
pain, often radiating down the legs (sciatica). Children may refuse to walk. 
Vertebral osteomyelitis is readily apparent through radionucleide scans.  A post-
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infectious spondyloarthropathy involving multiple joints has been described, and 
is believed to be caused by circulating immune complexes (3).  
 
1.11.2 Gastrointestinal complications 
B. melitensis is primarily foodborne and transmitted to humans via the 
consumption of unpasteurized milk and dairy products (as cheese). Foodborne 
brucellosis resembles typhoid fever. Some patients with the disease experience 
nausea, vomiting, and abdominal discomfort (2). 
 
1.11.3 Hepatobiliary complications 
The liver is commonly involved in brucellosis. Liver function tests can be normal 
or only mildly elevated. A spectrum of hepatic lesions has been described in 
cases due  
to B. melitensis, including scattered small foci of inflammation resembling viral 
hepatitis. Occasionally larger aggregates of inflammatory cells are found within 
the liver parenchyma with areas of hepatocellular necrosis. In other cases, small, 
loosely formed epitheloid granulomas with giant cells can be found. Acute and 
chronic cholecystitis has been reported in association with brucellosis (2). 
 
1.11.4 Respiratory tract complications 
Aerosol inhalation is a recognized route of transmission of brucellosis, especially 
in abattoirs where infected animals are slaughtered. A variety of pulmonary 
complications have been reported, including hilar and paratracheal 
lymphadenopathy, interstitial pneumonitis, bronchopneumonia, lung nodules, 
pleural effusions, and emphysema (3). 
 
 1.11.5 Genitourinary complications 
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Orchitis and epididymitis are the most frequent genitourinary complications of 
brucellosis in men. Usually unilateral, Brucella orchitis can mimic testicular 
cancer or tuberculosis. Although Brucella organisms have been recovered from 
banked human spermatozoa, there have been a few reports implicating sexual 
transmission. Renal involvement in brucellosis is rare, but it too can resemble 
renal tuberculosis. In women, rare cases of pelvic abscesses and salpingitis have 
been reported (12). 
 
 
 
1.11.6 Pregnancy and breastfeeding 
Brucellosis during the course of pregnancy carries the risk of spontaneous 
abortion or intrauterine transmission to the infant. Abortion is a frequent 
complication of brucellosis in animals, where placental localization is believed to 
be associated with erythritol, a growth stimulant for B. abortus. Although 
erythritol is not present in human placental tissue, Brucella bacteremia can result 
in abortion, especially during the early trimesters (12,11). 
 
1.11.7 Cardiovascular complications 
Infective endocarditis is the most common cardiovascular manifestation and most 
common cause of death from brucellosis. The aortic valve is involved more often 
than the mitral valve. Mycotic aneurysms, usually involving the middle cerebral 
artery, can be a neurological complication of infective endocarditis (16). 
Neurobrucellosis refers to a variety of neurological complications associated with 
brucellosis. Direct invasion of the central nervous system occurs in about 5% of 
cases of B. melitensis infection, and meningitis or meningoencephalitis are the 
most common manifestations. Brucella meningitis can be acute or chronic. 
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Analysis of cerebrospinal fluid (CSF) usually reveals elevated protein content, 
normal or low glucose concentration, and a lymphocytic pleocytosis. Brucella 
organisms are rarely isolated from CSF, but specific antibodies can be 
demonstrated in the CSF and serum. Other CNS manifestations of brucellosis 
include cerebral vasculitis, mycotic aneurysms, brain and epidural abscesses, 
infarcts, haemorrhage, and cerebellar ataxia. Peripheral nerve complications 
include neuropathy/radiculopathy, Guillain-Barré syndrome, and a poliomyelitis-
like syndrome (12). 
 
1.11.8 Cutaneous complications 
A variety of skin lesions have been reported in patients with brucellosis, 
including  
rash, nodules, papules, erythema nodosum, petechiae, and purpura. Occasionally, 
epistaxis, gingivorrhea, haematuria, and cutaneous purpura occur in association 
with severe thrombocytopenia, which has been ascribed to hypersplenism, bone 
marrow  
haemaphagocytosis, and/or anti-platelet antibodies (16). 
 
                 1.11.9 Opthalmic complications 
Although uncommon, a variety of ocular lesions have been reported in patients 
with  
brucellosis. Uveitis is the most frequent manifestation, and can present as chronic 
iridocyclitis, nummular keratitis, multifocal choroiditis or optic neuritis. Since 
Brucella organisms have not been isolated from the structures of the eye in 
humans, many of these lesions are considered to be late complications, possibly 
immunologically mediated (16). 
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1.11.10 Chronic brucellosis 
Chronic brucellosis should be reserved for patients whose clinical symptoms 
persist for 12 months or more from the time of diagnosis. Using this criterion, 
patients fall into three categories: (1) relapse, (2) chronic localized infection, and 
(3) delayed  
convalescence. Relapse is defined as the recurrence of characteristic signs and 
symptoms occurring at some time after the completion of a course of treatment. 
Patients with relapse characteristically have objective signs of infection, such as 
fever, and persistently elevated titers of IgG antibodies in their serum. Most 
relapses occur within six months after therapy, and relapse is not usually due to 
the emergence of antibiotic resistant strains (12). 
 
1.12 Treatment 
Brucellae are sensitive to a number of oral antibiotics and to aminoglycosides in 
vitro. Therapy with a single drug has resulted in a high relapse rate. Therefore,  
treatment with multiple antibiotics is encouraged. Combinations of doxycycline 
and streptomycin, rifampin and doxycycline, rifampin, streptomycin, and 
doxycycline, and rifampin with trimethoprim/sulfamethoxazole are commonly 
used for effective treatment of brucellosis and its manifestations. World Health 
Organization Expert Committee recommends the treatment of pregnant women 
with rifampin (12). 
 
1.13 Vaccination 
The Rev.1 live Brucella melitensis vaccine is the most widely used vaccine in 
control programs against brucellosis in small ruminants. When properly used, the 
Rev.1 vaccine confers a long lasting protection against field infections in a high 
proportion of animals. This vaccine however shows a considerable degree of 
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virulence and induces abortions when the first vaccine dose is administered 
during  
 
pregnancy (28, 29). 
The antibody response to vaccination cannot be differentiated from the one 
observed after field infection, and this therefore impedes control programs. 
Attempts have been made to develop new vaccines based on “rough” (R) strains 
or genetically modified strains of the Brucella species. Those vaccines await 
further evaluation in  
field experiments. Control programs focus on the proper application of 
vaccination as an indispensable step to eradicate Brucella melitensis   Control 
programs require a well functioning surveillance system, the co-operation with 
livestock owners and considerable financial support. The appropriate application 
of vaccination will result in suppression of the infection pressure and has been 
shown to reduce the zoonotic spread of the disease (29). 
 
1.14 Outline of the study 
Reported cases of brucellosis in Palestine are mainly diagnosed by serology tests 
and culture followed by identification by of phenotypic tests. However, up to 
now there is no data about the local circulating Brucella strains in comparison 
with the strains used in vaccine production. Hence, it is of epidemiological 
interest to see whether the allelic frequency in Palestinian Brucella circulating 
strains is similar to the one reported in other Mediterranean countries and to 
determine if vaccination selects for strains that have different genotypes from 
those used to make the vaccine, allowing the spread of escape mutants to the 
vaccine strain. Therefore, the current study was conducted, 
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1. To study the seroprevalence of brucellosis in sheep and goats suspected to 
have infected with Brucellosis by detecting antibodies in serum employing RBT 
and comparing it with CFT. 
2. To isolate and identify Brucella from milk with confirmation by molecular 
methods. 
3. To genetically characterize representative isolates of B. melitensis related to 
the  Rev 1 vaccine strain used here and isolates from different Mediterranean 
countries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
MATERIALS AND METHODS 
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2.1. Area of study 
The West Bank is a landlocked territory and the 
eastern part of the Palestinian territories was 
chosen for the study (Figure 2.1). The 
geographical location of the West Bank between 
the 31°21` and 32°33` latitude and between 
34°52` and 35°32` longitude, makes the area 
highly influenced by the Mediterranean 
climate.  The Mediterranean climate is 
characterized by a long, hot, dry summer and 
short, cool, rainy winter.  Rainfall is limited to 
the winter and spring months.  It usually starts in 
the middle of October and continues up to the 
end of April.  Snow and hail, although uncommon,  
may occur anywhere in the area especially to the west of and over the highlands. 
The total animal population in this area according to last statistic Ministry of 
Agriculture and directorate veterinary services and animals health 2009 are 
800.000 sheep and goats and 4886 bovines. 
 
 
 
2.2. Subjects and study  
This study on serological, cultural and molecular detection of Brucella infection. 
It was performed at the Master program in Clinical Laboratory Science, Birzeit 
University, Palestine between January and December, 2008. A total of 350 sera 
samples comprising of 302 from sheep, 48 from goats were collected from five 
different districts in the West Bank, Palestine. Eighty pooled milk samples were 
Figure2.1 Map of West Bank, 
Palestine 
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also included in this study (Table 2.1). None of the animals were vaccinated 
against Brucella. Also, these samples were also collected from the flocks when 
owners were infected by Brucellosis according to report by Ministry of Health. 
District Samples 
Serum Milk 
Sheep  Goat  Total Sheep  Goat  Total 
Hebron 180 22 202 29 6 35 
Jericho 47 4 51 25 10 35 
Ramallah 35 7 42 2 1 3 
Nablus 20 5 25 2 0 2 
Jenin 20 10 30 3 2 5 
Total 302 48 350 61 19 80 
Table 2.1: Distribution of the serum and milk samples collected from sheep and 
goats flocks in different districts of the West Bank. 
 
2.3. Collection of samples 
2.3.1. Animal sera 
About 5 to 10 ml of blood was collected aseptically from each animal from the 
jugular vein in a plain tube without EDTA. It was essential to avoid the shaking 
of the tubes (which contain blood) during transport to prevent hemolysis of the 
RBCs. The serum was screened immediately for Brucella melitensis by the Rose 
Bengal  
Plate Test (RBPT) as a screening test, and Complement Fixation Test (CFT) as 
the confirmatory test. If either of these tests were positive, the animal was 
considered infected with brucellosis.   
 
2.3.2. Milk samples 
Sheep and goat milk samples were collected in a sterile plastic vial in the 
morning. The milk samples were immediately cultured on Brucella agar medium 
(Oxoid).  
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2.4. Laboratory Procedure 
2.4.1. Rose Bengal Plate Test (RBPT)  
The Rose Bengal Plate Test antigen for Brucella was obtained from Jordan Bio-
Industries Center (JOVAC) Jordan.  The test was performed by a rapid slide 
screening method, according to manufacturer's instruction. Before performing the 
test, antigen and sera were brought to room temperature and aliquots of 30 µl of 
the serum were placed on a glass slide by micropipette. The antigen bottle was 
shaken well to ensure homogenous suspension and then one drop (30 µl) of Rose 
Bengal antigen was added. The antigen and serum were mixed thoroughly with 
the spreader and then the slide was rotated for four minutes. Definite clumping 
(agglutination) was considered as positive reaction (Figure 2.2). Positive and 
negative controls were used with each test plate (30, 31).   
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                2.4.2 Complement Fixation Test (CFT) 
The principle of in the complement fixation antigen-antibody reaction involved 
binding of the complement. Absence of antibody in animal’s serum leaves the 
added complement unfixed. The addition of an indicator, consisting of sheep red 
Figure 2.2 Rose Bengal Plate Test (RBPT) 
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blood cells sensitized with hemolysin (specific antibody to sheep red blood cells), 
to the reaction well enables any residual complement to be detected and 
visualized by the lysis of sheep red blood. Absence of complement and therefore 
presence of antibody in the animal’s serum is visualized by the sheep red blood 
cells 
rema
ining 
cont
act 
(Fig
ure 
2.3).  
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       2.4.2.1 Hemolysin titration 
To determine the minimum concentration required for 100% lysis of the 
sensitized        sheep red blood cells, the Minimum Hemolytic Dose (MHD), the 
following procedure is used:  An aliquot of 25 µl of veronal buffer saline 
(Biomerieux) was placed in each well of columns 2 -12 of the 96-well U-bottom 
microtitre plates (Figure 2.4).  An aliquot of 50 µl of diluted hemolysin 
(Biomerieux) solution in veronal buffer saline in a ratio 1:250 was placed in each 
well of the first column, followed by twofold dilution. Then 25 µl of complement 
(Biomerieux) was added to each well in the microtitre plate followed by the 
addition of 25 µl of 2% suspension of red blood cells (RBC).  
The plate was then incubated at 37°C for 30 minutes and subsequently checked 
for agglutination. The working solution of the hemolysin is considered as two 
folds higher than the observed agglutination.  
Figure 2.3: The principle of the Complement Fixation Test 
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 Figure 2.4: Orientation of the microtitre plate 
 
2.4.2.2 Complement Fixation Test Method 
Serum samples, positive and negative standards were diluted 1:5 in Veronal 
buffer saline and placed in a water bath at 56°C for 30 minutes. An aliquot of 25 
µl of Veronal buffer was added to all wells of the 96-well U-bottom microtitre 
plates. In the first column, 25 µl of the inactivated samples was added to wells 
of the first column, followed by a 2 fold dilution. An aliquot of 25 µl antigens 
(1:500 dilutions) and complement (1:30 dilution) was added to all wells of plate 
and incubated for 30 minutes at 37°C. A mixture of hemolysin working solution 
and 2% RBC solution was mixed in equal amounts and prepared 15 minutes 
before the end of the incubation of the previous step. An aliquot of 25µl of this 
mixture was added to all wells of the plate followed by an incubation period of 
30 minutes at 37°C. The plate was shaken three times during this incubation 
period.  The plate was then removed from the incubator and placed at room 
temperature for a total of two hours before interpretation. Wells that show 
complete lysis of the sensitized red blood cells were considered negative while 
wells with sedimentation of the sensitized red blood cells were considered 
positive (Figure 2.5) (29) 
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2
.4.3. Isolation and Identification of Brucella Culture from Milk samples 
The milk collected from seropositive flock and positive control, Rev 1 vaccine 
strain, were cultured on Brucella agar (Oxoid) supplemented with Brucella 
supplement (Oxoid) and 7% sterile horse serum (Oxoid). Growth appeared after 
24 hours for the control strain while it took 3 to 7 days for the cultured milk. 
The isolates were identified as Brucella according to colonial and microscopic 
morphology, oxidase (Oxoid) positive and urease (Oxoid) positive. 
 
2.4.4. Genomic DNA Preparation  
DNA was extracted from both positive milk cultures and collected milk samples 
from seropositive animals using DNA extraction Nucleospin kit (Promega, 
Germany) according the protocol suggested by the manufacturer. An aliquot of 
200 µl of milk or a suspension of 200 µl of bacteria was mixed with 180 µl pre-
lysis buffer (T-1) and 50 µl proteinase K, vortexed and placed in a dry bath at 
56ºC for 3 hours, then 200 µl of lysis buffer (B-3) was added, vortexed and 
incubated at 72ºC for 10 min in a dry bath as before. Subsequently, 200 µl of 
ethanol was added, to make the DNA float. The DNA sample was placed in the 
tube within the column where the DNA will be bound. The tube was then 
centrifuged for 1 min at 8000 rpm, washed twice with 500 µl of washing buffer 
(B5).  The membrane in the tube was dried by centrifugation for 1 min at 14 000 
rpm and then the DNA sample was eluted by adding 50 µl elution buffer (BE 
buffer) followed by placing the filter in a sterile collection tube and centrifuged 
for 1 min at 8000 rpm where the DNA was   
 
collected in the sterile collection tube.  
Figure 2.5 Complement Fixation Test in Microtiter Plate 
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2.4.5. Primers  
A set of the primers used in the PCR reactions is summarized in Table 2.2. 
Sequences for primers IS711G, IS711, BM and BMR7521 were obtained from 
the literature (37, 27, 28). DNA sequences of primers for Brucella used in DNA 
sequencing were constructed via Search for open reading frames (ORF 1) and 
putative gene used in the DNA sequence of Brucella melitensis was performed 
with a computer-assisted program (Primer3 Output; 
http://frodo.wi.mit.edu/primer3). The primer sequence was selected with the 
following properties: 20-25 nucleotides starting with at least one G or C at the 5’, 
terminated with GC at 3’end and the GC content of about 50%.  
 
2.4.6 Polymerase Chain Reaction 
Polymerase Chain Reaction (PCR) amplification was performed using a 
MasterCycler (BioRad Laboratories, Inc., Hercules, CA). The DNA was 
amplified using the primers listed in Table 2 below. Each reaction mixture was 
prepared by placing 12.5 µl master mix with loading dye obtained from 
Promega, Germany (0.5 U Taq polymerase, 10 mMTris – HCl, 3 mM MgCl2, 
50 mMKCl, 0.1% Triton, 200 mM and the four nucleotides), 6.5 µl nuclease 
free PCR water (Qiagen, Germany), 0.5 µl 20 nmol forward primer and 0.5 µl 
20 nmol reverse primer (Syntezza, Israel) and 5 µl DNA template. PCR 
amplification was performed as summarized in Table  
                  2.3.  
 
Primer 
name 
Oligonucleotide sequences (5'-3') Amplified 
product (bp) 
Target species 
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Table 2.2: The sequences of primers for Brucella used in this study 
 
 
Primers  
 
                            Cycling conditions 
Initial denaturation  Denaturation Annealing Extension 
IS711G 95ºC, 120 s 95ºC, 30 s 51ºC, 45 s 72ºC, 30 s 
IS711BM 95ºC, 120 s 95ºC, 30 s 51ºC, 45 s 72ºC, 30 s 
  Repeated for 35 cycles 
ORF 1  95ºC, 120 s 95ºC, 30 s 51ºC, 45 s 72ºC, 30 s 
BMR752 95ºC, 120 s 95ºC, 30 s 51ºC, 45 s 72ºC, 30 s 
  
Repeated for 35 cycles 
 
Table 2.3 Conditions of thermal cycling for different primer pairs in PCR 
             
                 2.4.7. Agarose Gel Electrophoresis  
DNA products generated via PCR were mixed with 2 µl of agarose gel loading 
dye and separated on a 2% agarose (Promega, Germany), run at 100 V in a gel 
electrophoresis unit, BioRad, Germany until the dye front was approximately 1 
inch from the bottom of the gel.  A 100-bp DNA ladder molecular weight 
standard was visualized on gels to determine the size of linearized DNA samples 
IS711G F- GGT TGT TAA AGG AGA ACA GC 
R – GAC GAT AGC GTT TCA ACT TG 
600 bp Brucella spp. 
IS711B
M 
F – TGC CGA TCA CTT AAG GGC CTT CAT 731 bp B.melitensis 
 
 R – AAA TCG CGT CCT TGC TGG TCT GA 
BMR752 F - CAG GCA AAC CCT CAG AAG C 
R - GAT GTG GTA ACG CAC ACC AA 
752 bp B.melitensis 
Rev.1 
ORF 1 F – GAA CCA GAA TAC GGC AAA A 
R – CTC ACG GCT GTT CTC CTT TAA CA 
2 kb DNA sequence 
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being tested.  Gels were incubated in 1.0 µg/ml ethidium bromide for 5-8 minutes 
and destained in dH2O for 30 minutes.  Gels were photographed on a 392-nm 
wavelength transilluminator (BioRad, Germany) and the resultant bands were 
recovered using a Polaroid Gel Documentation System.  
 
2.4.8. PCR Purification procedure for sequencing 
This step was essential to eliminate undesirable components that may be present 
and to obtain a clean concentrated product adequate for sequencing.  Purification 
of the positive PCR products was conducted by using the MinElute PCR 
purification kit (Qiagen, Germany).  The purified PCR products were then re-
amplified in a total volume of 50 µl instead of the 25 µl previously used to get 
reasonable quantities adequate for sequencing.  
In brief, 250 µl of sodium iodide was added to 50 µl of the positive PCR product. 
The mixture was then gently vortexed and added to the DNA binding column, 
centrifuged to elute unbounded components and washed twice with the washing 
buffer included in the kit. Bound DNA (PCR product) was eluted with 10 µl 
ddH2O. Agarose gel electrophoresis was then carried out using 2 µl products to 
ensure purity and concentration prior to sequencing.  
 
2.4.9. DNA sequencing  
Sequencing of the purified PCR products was performed at Bethlehem University 
using the sequencer ABI PRISM 301 Genetic analyzer.  Sequencing was 
performed for both the reverse and forward primer in each reaction with a mix of 
labeled nucleotides (Big Dye Terminator V 1.1).  
 
2.4.10. DNA analysis. 
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The open reading frames (ORFs) sequences of the two representative B. 
melitensis isolates and the vaccine strain (B.melitensis Rev.1) were compared to 
the Genbank sequences of reference Brucella with gaps treated as “missing”, as 
per the PAUP rule. Sequence comparisons to reference Brucella were conducted 
using CLC Main Workbench software; (Website, www.clcbio.com, version 5.6.1, 
2009) Alignments of individual Brucella sequences were created using the 
ClustalX program ( BLAST ).  The phylogenetic relationships between the 
Brucella isolate and selected reference Brucella were estimated from their 
nucleotide sequences by employing the neighbour-joining algorithm in the 
program NEIGHBOR in the Phylip program package version 3.52. Bootstrap 
analysis on 1000 replicas was performed using the SEQBOOT and CONSENSE 
programs in the Phylip package. 
  
 
2.5 Statistical analysis 
To compare the sensitivity and specificity between the tests used in our study, the 
statistical formula given by Samad et al. (33) was used as described below. 
 
 
 
            
 
 
 
The notations used above are defined as. 
A: Number of samples positive to both conventional and the gold standard tests 
 
Test 
Gold standard test  
Total 
Positive Negative 
 
The test 
Positive to 
be 
compared 
Positive A B A+B 
Negative C D B+D 
Total A+C B+D A+B+C+D 
- 34 - 
 
B: Number of samples positive to conventional but negative to the gold standard 
test 
C: Number of samples negative to conventional but positive to the gold standard 
test 
D: Number of samples negative to both conventional and the gold standard tests 
A+B+C+D = Total number of samples  
Sensitivity: It is the capacity of the test to detect diseased animals, when 
compared with the gold standard test (A/A+C x 100). 
Specificity: It is the capacity of the test to detect non-diseased animals, when 
compared with the gold standard test (D/B+D x 100) 
 
 
 
CHAPTER III 
RESULTS 
3.1. Serological Results 
Brucellosis is a zoonotic infection with a variety of clinical pictures, and may be 
confused with a number of other illnesses in diagnosis. Thus, various serological 
tests are employed with varying degree of sensitivity and specificity.  Isolation of 
organisms is tedious, cumbersome and time consuming thus it is generally not 
being followed in routine diagnostic laboratories. In the present study, the sera of 
350 animals with clinical suspicion of Brucellosis comprising of 302 from sheep 
and 48 from goat collected from five different districts in the West Bank, 
Palestine were analyzed by Rose Bengal Plate Test (RBPT) and Complement 
Fixation Test (CFT). Culture and PCR techniques were used for detection of 
Brucella organisms and Brucella DNA, respectively, in the milk samples. The 
percentage of the positive brucellosis sera was found to be as follows: 31 % in 
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sheep sera and 52% in goats sera by RBPT, giving overall seroprevalence of 
34 %. Whereas the overall seropositivity using CFT was 31%, 29% in sheep sera 
and 44% in goats sera (Table 3.1) 
 
 
 
 
 
 
Animal 
sp. 
Total 
samples 
RBPT CFT 
Positive 
samples 
(%) Positive 
samples 
(%) 
Sheep 302 94 31 87 29 
Goats 48 25 52 21 44 
Overall 350 119 34 108 31 
 
 
Table 3.1 The percentage of the positive brucellosis in serum samples from 
different animals by RBPT and CFT 
 
To find out relative sensitivity and specificity of RBPT and CFT, cross 
tabulation of results of RBPT with that of CFT, considering CFT as a gold 
standard test, are shown in Table 3.2. 
Test CFT  
Total 
Sensitivity 
(%) 
Specificity 
(%) 
Positive Negative 
RBPT Positive 102 27 129  
90.3 
 
89 Negative 11 210 221 
Total 113 237 350 
                  Table 3.2 Evaluation of RBT in comparison to CFT 
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                  3.2. Isolation and Identification of Brucella 
Milk samples collected from seropositive animals were subjected to 
bacteriological examination. Brucella organisms were detected in milk samples 
collected from 38 (47.5%) 80 seropositive animals only. All cultures were 
typical of isolates of  
Brucella in morphology, colonial appearance and growth characteristic on 
Brucella agar medium. The round, glistening and smooth or mucoid colonies on 
plates of BAM were suspected to be of Brucella (Figure 4.1). All the isolates 
were oxidase positive and urease positive. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3. Testing of milk samples with IS711 PCR  
IS711 elements, also known as IS6501, have been described as useful targets for 
molecular characterization of Brucella species and biovars.  All species of the 
Figure 3.1 Brucella agar plate growing Brucella  
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Brucella genus contain several copies (between 10 and 40) of an insertion 
sequence,  
IS711. The position of copies of this insertion sequence appears to differ in each 
species and this can be used to discriminate between them. A new polymerase 
chain reaction test, called IS711 PCR was developed. It was based on a 
combination of a primer bound on the sequence of I IS711 with a second primer 
chosen arbitrarily. The patterns obtained reflect the position of the insertion 
sequence in the genome. By testing the milk samples collected in our study, all 
34 positive (42.5%) milk samples detected by bacterial isolation were also 
detected by IS711 PCR. Furthermore, with the IS711 PCR, we were able to 
additionally detect 24 (30%) of the samples that were negative by the bacterial 
isolation method. Table 3.3 shows the number of positive milk samples detected 
by bacterial isolation and IS711 PCR. Brucella species-specific DNA fragments 
with 600 bp were amplified from all isolates and no DNA was observed in 
negative control samples (Figure 3.2)  
 
 
 
 
 
 
 
 
 
 
Method Total milk samples Positive samples detected 
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No. % 
Bacterial isolation 80 38 47.5 
IS711  PCR 80 62 77.5 
 
Culture 
PCR from cultured 
bacteria 
PCR from milk 
Brucella 
group 
B. melitensis B. group B.melitensis B.abortus 
No % No % No % No % No % No % 
38/80 47.5 38/38 100% 38/38 100% 62/80 77.5 42/80 52.5 29/80 36.3 
Table 3.3.  Detection of Brucella spp. in milk samples by bacterial isolation and 
IS711 PCR 
 
 
 
 
 
 
 
 
Figure 3.2 Representative IS711 PCR profiles of DNA from 5 Brucella isolates. 
Lane L, molecular sizes marker (100-bp ladder DNA); NC, Negative control 
contained no template; PC, Positive control; Lane 1-5, Brucella species 
 
To find out relative sensitivity and specificity of Brucella culture and PCR, 
cross tabulation of results of culture with that of PCR, considering PCR as a 
gold standard test, are shown in Table 3.4. Sensitivity of culture method was 
found to be of 61.3%, with considering IS711 PCR as a gold standard test while 
specificity was found to be of 100.0%. 
Test PCR  Sensitivity Specificity 
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                 Table 3.4: Evaluation of RBT in comparison to CFT. 
B. melitensis was isolated from 42 out of 80 (52.5%) milk samples examined in 
this study. The identification was performed by PCR utilizing primers specific to 
IS711 gene of B. melitensis. B. melitensis-specific DNA fragments with 731 bp 
were amplified from all isolates and no DNA was observed in negative control 
s
a
m
p
l
e
s
 
(
Figure 3.3). 
 
 
 
 
 
 
Positive Negative Total (%) (%) 
Cult
ure 
Positive 38 0 38  
61.3 
 
100 Negative 24 18 42 
Total 62 18 80 
- 40 - 
 
 
 
Figure 3.3 Representative PCR profiles of DNA from 5 Brucella melitensis 
isolates using primer of B. melitensis. Lane L, molecular sizes marker (100-bp 
ladder DNA); NC, Negative control contained no template; PC, Positive control; 
Lane 1-5, Brucella species 
 
 
 
B. abortus was distinguished by 
amplification of a specific 240-bp 
fragment in 36% (29/80) of the milk 
samples. A representative example of the 
PCR with B. abortus DNA results is 
presented in Figure 3.4.  
            
   
Figure 3.4 PCR profile of DNA from  
           a representative B. abortus isolate                                        
              using primer of B. abortus.  
           Lane L, molecular sizes marker  
     (100-bp ladder DNA); NC, Negative 
control contained no template; PC, Positive control;   
         Lane 29, Brucella species 
Distinguishing vaccine strains from strains that cause infections among 
vaccinated herds in the field is essential. To accomplish this, our PCR-based, 
species-specific assay was used to identify Brucella melitensis vaccine strains 
Rev 1 using primers specific for Rev1.  
These primers were selected on the 
basis of polymorphism 
which occurs at a locus containing 
the genetic element IS711 arising. 
This new primer was designed to 
differentiate Rev 1 from other B. 
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melitensis strains by PCR amplification of an additional 752-bp product. Our data 
confirmed the expected paradigm for B. melitensis strains and the vaccine strain 
Rev.1. All our B. melitensis field isolates were different from the vaccine strain 
Rev.1 by the absence of the 752-bp fragment (Figure 3.5).  
 
 
 
 
 
 
 
 
Figure 3.5 Identification and differentiation of all B. melitensis and  B. melitensis 
Rev1 vaccine strains by PCR. Lane 1, Negative control; Lane 2-4, B. melitensis 
Rev1; Lane 5-6, B. melitensis field strain 
 
 
 
3.4. Genetic analysis  
3.4.1. B. melitensis field isolates and commercial vaccine strain Rev.1 
alignment.  
Two of the B. melitensis isolates and the vaccine strain B. melitensis Rev1 were 
used for genetic strain phylogeny. For this purpose, Hemagglutunin (HA) gene 
was PCR-amplified from two field isolates and   the vaccine strain B. melitensis 
Rev1 using the primers ORF-1F and ORF-1R. The amplified PCR products were 
subsequently sequenced (Figure 3.6,a b, c) at Bethlehem University using the 
Genetic analyzer (sequencer) ABI PRISM 301. The primers used for PCR are 
indicated in Table 2.2.  
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Figure 3.6, a.  DNA sequence of B. melitensis isolate number 1  
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Figure 3.6, b.  DNA sequence of B. melitensis isolate number 2 
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Figure 3.6, c.  DNA sequence of B. melitensis Rev1  
The ORFs sequences of the two field isolates were aligned and compared with 
other GenBank-accessible gene sequences of B. melitensis and other Brucellae 
spp. using version 2.0 of BLAST. These sequences were identical to that of the 
recent sequence of type strain of B. melitensis (ATCC 23456, GenBank access no: 
CP001489.1 and AE008918.1),confirming that the isolate belonged to the genus 
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Brucella and were also corresponding to the Brucella hemagglutinin or 
Glycoprotein X precursor gene sequences. Several other GenBank-deposited 
sequences of B. melitensis biovar/strain, ovis, suis, and canis were also found to 
be identical to isolate sequences of the current study. (Table 3.5). 
Accession Description E value* Identity (%) 
CP001489.1 Brucella melitensis ATCC 23457 chromosome II, 
complete sequence 0.0 95% 
AE008918.1 Brucella melitensis 16M chromosome II, complete 
sequence 0.0 95% 
CP000709.1 Brucella ovis ATCC 25840 chromosome II, 
complete sequence 0.0 95% 
CP000912.1 Brucella suis ATCC 23445 chromosome II, 
complete sequence 0.0 95% 
CP000873.1 Brucella canis ATCC 23365 chromosome II, 
complete sequence 0.0 95% 
AE014292.2 Brucella suis 1330 chromosome II, complete 
sequence 0.0 95% 
                             *Expect value; The lower the E-value, or the closer it is to zero, the more "significant" the match 
is.   
 
 
Table 3.5 Genetic homology of the two B. melitensis isolated in Palestine with 
related sequences available in GenBank. 
In Palestine, whole cell Brucella vaccine is still the only kind of Brucella 
vaccine being used. Up to now there is no data about the local circulating 
Brucella strains in comparison with the strains used in vaccine production. 
Hence, it is of epidemiological interest to see whether the allelic frequency in 
Palestinian Brucella circulating strains is similar or not to the one reported in the 
other Mediterranean countries and to determine if vaccination selects for strains 
that have different genotypes from those used to make the vaccine, allowing the 
spread of escape mutants to the vaccine strain. Therefore, the ORFs sequences 
of hemagglutinin gene of two B. melitensis field isolates isolates were Clustal 
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aligned and compared with the vaccine strain Rev.1 using version 5.6.1 of 
CLCL Main Workbench. A good alignment was observed between the two B. 
melitensis isolates and the vaccine strain (Figure 3.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Nucleotide comparison between ORFs of the homology gene of B. 
melitensis field isolates and the vaccine strains. Dots represent nucleotides similar to 
the consensus.  
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Figure 3.7. (Continued ). 
 
3.4.2. Restriction analysis 
We analyzed the PstI digestion profiles of the ORFs sequenced fragment of 
hemagglutinin gene obtained from the field isolates and that obtained from 
vaccine strain using version 5.6.1 of CLCL Main Workbench. As can be seen in 
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Figure 3.8 and Table 3.6, PstI digestion of the field isolates (lines 2 and 3) 
produced a uniform identical to that obtained for vaccine strain Rev.1, however, 
The HaeIII digestions of the amplified fragments from the vaccine strain Rev.1 
yielded a different pattern (line 2). 
Sequence Name Pattern Length Overhang Number 
of cut 
sites 
Cut 
position(
s) 
Brucella melitensis 
isolate 1/P 
PstI ctgcag 6 3' 2 418, 910 
Brucella melitensis 
isolate 2/P 
PstI ctgcag 6 3' 1 416 
Brucella melitensis 
Rev1/P 
HaeIII ggcc 4 Blunt 2 221, 283 
Brucella melitensis 
Rev1/P 
PstI ctgcag 6 3' 1 419 
 
Table 3.6. Restriction site analysis of the ORFs of B. melitensis field isolates and 
the vaccine strains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Restriction map of the ORFs of B. melitensis field isolates and the 
vaccine strains. 
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3.4.3. Phylogenetic analysis  
The results of a maximum likelihood phylogenetic analysis by creating a Clustal 
tree using version 5.6.1 of CLCL Main Workbench of the two B.melitensis field 
isolates with other GenBank-accessible gene sequences of B. melitensis isolated 
from several Mediterranean countries are shown in Figure 3.8. This tree sorts the 
Brucella sequences studied here into three lineages (1-3). Each node received 
100% bootstrap. Although the tree is technically branching, the shortness and 
suboptimal support of those branches in the lineage number 1 suggest a higher 
average of similarity between Palestine/Israel/France/Spain Brucella strains; they 
appear to have radiated explosively. The tree generated (Figure 3.9) also shows, as 
expected, that strain with an accession number AY518304 which belongs to 
Israeli strains is the closest relative to our Brucella field isolates.  
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Figure 3.8.  A distance phylogenetic tree based on the partial nucleotide 
sequences of the ORFs sequences of two selected  B. melitensis field isolates and 
GenBank-accessible gene sequences of B. melitensis isolated from several 
Mediterranean countries. Horizontal distances are proportional to genetic distance. 
P; Palestine; I, Israel; F, France; S, Spain; C,Cyprus, T, Turkey; SW, Switezerland. 
The tree is rooted to version 5.6.1 of CLCL Main Workbench. 
 
 
 
 
 
 
 
 
CHAPTER IV 
DISSCUSSION 
Brucellosis is a major bacterial zoonosis of global importance (3). The disease is 
manifested by abortion and infertility and caused by Brucella species Gram-
negative facultative intracellular bacteria. Six species in the genus of Brucella are 
currently recognized on the basis of the phenotypic characteristics, antigenic 
properties and host distribution (6).  Brucella melitensis is the main etiological 
agent of brucellosis and the most important pathogenic Brucella species for 
humans causing clinically apparent human brucellosis. Brucellosis is 
geographically distributed in Mediterranean region, Middle East, parts of Africa, 
Western Asia and Latin America (7). B. melitensis is a big problem in Palestine 
and is the main cause of abortion in sheep (7).  
In Palestine, diagnosis of brucellosis in animals is based mainly on clinical signs, 
serological and bacteriological investigations. However, B. melitensis strains 
isolated or detected in Palestine have not been genetically characterized. Since 
isolation and genotyping of the infectious agents are vital for management 
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practices of the farms and for the ability of the country to implement and finance 
prevention and control program, we isolated B. melitensis from sheep and goats in 
the West Bank, Palestine and characterized it phenotypically, serologically and 
genetically.   
The application of multiple serological assays currently available for the detection 
of Brucella antibodies in various species of animals indicates that no single test 
can detect all infected animals and therefore, combination of serological tests 
should include more sensitive tests designed to reduce the number of false 
negative reactions which contribute to the persistence of infection as a herd 
problem.  
In the present study, we comprehensively compared the RBT and CFT methods in 
animals (sheep and goats) in order to evaluate their applicability as alternative 
methods in surveillance programs. The obtained results revealed that in RBPT and 
CFT, 119 (34%) and 108 (31%) were positive respectively (Table 3.1). When 
CFT was used as the reference, the sensitivity and specificity of RBT were being 
in the range of 90.3% and 88.9%, respectively. The obtained results do not 
mention the prevalence of Brucellosis in Palestine, since our samples have been 
taken from animals with signs of Brucellosis. This research indicates that 
brucellosis is still representing a big problem that affects the domestic animals in 
this part of Palestine, that agree with the previous seroepidemiologic studies (34).    
The higher number of RBT 119 (34%) reactors compared to CFT 108 (31%) is the 
result of high number of false positive results of RBT.  This result from the 
examiner recording any slight agglutination which may neither be neither accurate 
nor recommended by the manufacturers as positive. Keeping in mind the well 
documented problem of extensive serological cross-reactions of the RBT with 
other bacteria including Yersinia enterocolitica O:9, Campylobacter fetus, Vibrio 
cholera, Bordetella bronchiseptica and Salmonella species which are commonly 
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found in sheep and goats, it is highly likely that a great number of these samples 
were indeed false positives (35).  
From the results obtained by RBT and CFT, we concluded that it was impossible 
to  
detect all infected animals using a single test. The combination of RBT with CFT 
is recommended since the CFT method is one of the superior serological tests as 
reported (34).  
Bacteriological examination of milk samples obtained from 80 serologically 
positive animals revealed the recovery of Brucella isolates from only 38 (47.5%) 
samples. This indicated that the sensitivity of serological test was higher than that 
of the culture method. The same conclusion was reached by Hamdy and Amin (36) 
who suggested that the most specific diagnostic test involves isolation of the 
causative organism, but this suffers from the drawback of requiring a long 
incubation period and low sensitivity especially in the chronic stage of the disease. 
Moreover, the culture material must be handled carefully as the Brucella organism 
is a class III pathogen. 
Although bacteriological isolation and identification of Brucella from culture has 
been considered to be the gold-standard, PCR is reliable in diagnosis of 
brucellosis. Taking into consideration the ability of PCR to be applied directly on 
milk specimens, it is more advantageous to use for diagnosing brucellosis than 
culture (27). In this study, we report the performance of PCR assay for the 
detection of Brucella species in milk samples. PCR was able to increase the 
number of positive milk samples which were negative by bacterial isolation.  
When PCR was used as the reference, the sensitivity and specificity of isolation of 
Brucella were being in the range of 61.3% and 100%, respectively. 
Even though PCR is more sensitive, more rapid and less biohazardous than 
cultural  
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techniques, the isolation of the organism is still accepted as gold standard. The 
culture  
isolation followed by the confirmation by PCR in this study is an another 
approach of diagnosis since PCR confirmation can fasten the identification at 
species level while remaining isolates can provide material for further biologic, 
phenotypic and antigenic studies. 
Historically, Brucella cell components specific for cell adhesion and invasion 
have not been characterized, and attempts to detect invasin genes have failed. 
With the completion of entire Brucella species genomes, specifically B. melitensis 
16M, studies have been and are currently being done to detect and characterize 
novel genes that may be involved in Brucella pathogenicity. Of particular note is a 
putative hemagglutinin gene found within the B. melitensis genome that is absent 
in B. abortus (37). The gene is present in B. suis and B. canis with minor 
nucleotide substitutions. There are two copies of the gene in B. ovis. The study 
utilized the hemagglutination test (HA), which has been extensively used for 
molecular detection or taxonomic analyses of many different bacterial species. 
This putative gene was PCR-amplified from two B. melitensis field isolates using 
the primers ORF-1F and ORF-1R.  The PCR fragments sequenced and aligned 
with other GenBank-accessible gene sequences of B. melitensis and other 
Brucellae spp.  The finding of identical sequence from Brucella in Palestine with 
the hemagglutinin gene consensus gene sequences from divergent GenBank-
accessible gene sequences also confirms that this gene sequence among Brucella 
spp. is extremely conserved. Since then, this method was extensively used to 
genotype Brucella isolates. This method, therefore, was carried  
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out to compare two of the B. melitensis isolate in the current study with Rev.1 
strain  
of B. melitensis.   
The nucleotide alignment of hemagglutinin ORFs results showed close similarities 
of the two field isolates to the current vaccine strains. However, the results of 
restriction analysis presented in this study have highlighted some of the potential 
hazards associated with use of the Rev.1 vaccine in Palestine control programs. 
Restriction analyses showed that the B. melitensis described here demonstrated 
restriction profile different from Rev.1 strain suggesting that field strain of B. 
melitensis in Palestine may be genetically different from the vaccine strain of the 
same organism. Although there are no studies on the capacity or efficiency of this 
vaccine for protection of brucellosis in this region, the field strains need to be also 
antigenically characterized and compared with the vaccine strain in order to better 
evaluate potential of Rev.1 vaccine. This antigenic determination should be a 
subject for a further study to establish a base for vaccine developments if 
necessary. Phylogenetic analysis provides a method of assigning strains to groups 
on the basis of similarities. The phylogenetic analysis strongly suggested that the 
two Palestinian Brucella field isolates and the Brucella isolates from Israel, 
France, and Spain are closely related. The phylogenetic tree presented in Figure 
3.9 also shows, as expected, that strain with an accession number AY518304 
which belongs to Israeli strains is the closest relative to our Brucella field isolates. 
These results demonstrated conclusively that an Israeli Brucella has been 
transmitted to sheep and goats in Palestine. As show study (38) that’s atypical 
strain characterized in Israel raised the possibility that this strain  
 
originated from a mutation of the vaccine stain. 
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In conclusion, further studies are needed to identify the route of transmission of 
Brucella into sheep and goats in Palestine. 
 
- 56 - 
 
Conclusion and Recommendations  
1. This study has shown that the zoonotic brucellosis (Brucella abortus) is still 
acting threat as a public health problem in Palestine.  
2. No single serological test can detect all infected animals by Brucella and 
therefore, combination of serological tests should include more sensitive tests 
designed to reduce the number of false negative reactions which contribute to the 
persistence of infection as a herd problem.  
3. Comparatively PCR was found more suitable method for detection Brucella in 
milk as compared to cultural methods because more numbers of milk samples 
were found positive by this method as well as all culturally positive bovines also 
found positive in PCR. 
4. Nucleotide alignment and Phylogenetic tree analysis of hemagglutinie gene 
revealed that the current representative isolate of B. melitensis  obtained from our 
collection  was genetically close to the isolates from different Mediterranean 
countries, particularly those from France, Spain and Israel, however, different 
from vaccine (Rev.1) 
Base on the outcome results, the following recommendations should be made 
to improve the farm management practices and to reduce the risk of 
brucellosis in the whole country:  
1. For the continued rise of public awareness of brucellosis, it is necessary to raise 
the level of health knowledge and farm management practices among the public 
and the farmers.  
2. Adequate epidemiological studies are is necessary to implement correct country 
vaccination strategy should be discussed.  
3. In the future, further study is necessary to be done about in investigations the 
risk status on the public health issues related to brucellosis. e.g. cohort study are 
important in investigations to identify risk factors associated with brucellosis in  
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4. The field strains need to be antigenically characterized and compared with the 
vaccine strain in order to better evaluate potential of Rev.1 vaccine. This antigenic 
determination should be a subject for a further study to establish a base for 
vaccine developments if necessary.  
5. Development more safety vaccine against Brucellosis of animals. 
6. Further studies are needed to identify the route of transmission of Brucella into 
sheep and goats in Palestine. 
 
 
 
 
 
 
 
 
 
 
 
REFERENCE 
1. Pappas G, Akritidis N, Bosilkovski M. Mile. Brucellosis. The New England 
Journal of Medicine; 352:2325-36, 2005 
 
2.  Corbel M. Brucellosis in human and animals. World Health Organization, 
2006 
 
- 58 - 
 
3. Cutler S and Cutler R. Brucellosis remains endemic in the Mediterranean basin, 
Middle East, Western Asia, Africa and South America. The biomedical scientist, 
April 2006 
 
     4. European commission health and consumer protection directorate  
     general  Brucellosis in sheep and goat, 2001 
 
               5. Young E.  An overview of human brucellosis. Clinical Infectious  
               Diseases 21:283-290, 1995 
 
               6. Shimshony A. Epidemiology of emerging zooneses in Israel. Emerg Infect Dis; 
               3: 229-238, 8. 1997 
 
     7. Refai M. Incidence and control brucellosis in the Near East region.  
     Vet Microbiol;    90: 81-110, 2002 
 
 
               8. Awad R. Human brucellosis in the Gaza Strip, Palestine Eastern  
               Mediterranean Health Journal  Volume 4, Issue 2, 225-233, 1998 
 
 9. Pishva E, Salehi M. First report of isolation of Brucella melitensis, vaccine 
strain Rev 1 as a source of cattle infection in Iran. Journal of Science Islamic 
Republic of Iran 19 (1), 19-23, 2008 
 
10. Directorate of veterinary services and animal health and UNDP archive 
documentation. Ministry of Agriculture, 2009 
 
- 59 - 
 
11.  Alton G, J.  Forsyth. Brucella., 2008 
 
12. Food and Agriculture Organization of the United Nations, World 
Organization for Animal Health , Word health organization Brucellosis in humans 
and animals, 2008 
 
13. Al-Kharfy T. Neonatal brucellosis and blood transfusion: case report and 
review of the literature. Ann Trop Paediatr, 21:349-362, 2001 
 
14.  Allardet-Servent A, Bourg G, Ramuz M et al. DNA polymorphism in strains 
of the genus Brucella. J. Bateriol, ; 170:4603-4607, 1998 
15. Muler W, Adams L, Ficht T et al. Brucella induced abortion and infection in 
bottlenose dolphins (Tursiops truncates). Zoo wield Med; 30:100-110, 1999 
16.  Koneman’s, Color atlas and Textbook of diagnostic microbiology, 2006 
 
17. Gandara B, Merino A, Rogel M et al. Limited genetic diversity of Brucella 
species. J. Clin microbiology; 39:235-240, 2001 
 
18. Lecaroz C, Blasco-Prieto M, Burrell M. Intracellular killing of Brucella 
melitensis in human macrophages with microsphere-endocapsulated gentamycin. 
Journal of Antimicrobial Chemotherapy, 58, 549-556, 2006 
 
19. Dieterson P, Gummon et al. The characteristic of a variant strain of Brucella 
melitensis. Onderstepoort J. Vet Res, 55(1), 15-7, March 1981 
 
20. Banai M, Mayer I and Cohen A. Isolation, Identification and Characterization 
in Israel of Brucella melitensis Biovar 1 Atypical Strains Susceptible to Dyes and 
- 60 - 
 
Penicillin, Indicating the Evolution of New Variant. Journal of Clinical 
Microbiology, 
               p. 1057-1059, May 1990 
 
21. Cloeckaert A, Gragon M et al. Identification of Brucella melitensis vaccine 
strain by PCR-RFLP based on a mutation in the rpsL gene; Vaccine 20, Issue 19-
20, p.2546-2550, June 2002 
 
22. Chachra D, Saxena H, Kaur G et al. Comparative efficiency of Rose Bengal 
plate test, standard tube agglutination test and Dot ELISA in immunological 
detection of antibodies to Brucella abortus in sera; Journal of Bacteriology 
Research Vol. 1, p 030-033, June, 2009 
 
23. Unver A, Erdogan H. Isolation, identification and molecular characterization 
of Brucella melitensis from aborted sheep fetuses in Kars, Turkey; Revue Med. 
Vet., 157, 1, 42-46, 2006 
 
24. Vemulapalli R, McQuiston J, et al. Identification of an IS711 element 
interrupting the wboA gene of B. abortus vaccine strain RB51 and PCR assay to 
distinguish strain RB51 from other Brucella spp and strains; Clinical and 
Diagnostic Laboratory Immunology, p. 760-764, 1999 
 
25. Ilhan Z, Solmaz H, et al. Detection of Brucella melitensis DNA in the milk of 
sheep after abortion by PCR; Arch. Med. Vet. 40, N2, p. 141-146, 2008 
 
- 61 - 
 
26. Leal-Klevezas D, Martinez-Vazquez I, et al. Single – step PCR for detection 
of Brucella spp from blood and milk of infected animals; Journal of Clinical 
Microbiology, p. 3087-3090, 1995 
 
27. Lopez-Goni I, Garcia-Yoldi D, et al. Evaluation of a multiplex PCR assay 
(Bruce-ladder) for molecular typing of all Brucella species, including the vaccine 
strains; Journal of Clinical Microbiology, p. 3484-3487, 2008 
 
28. Perry Q, Xavier B, et al. Brucella melitensis: the evaluation of a putative 
hemagglutinin gene’s effect on virulence in the caprine model; 2007 
 
29. Berhe G, Belihu K, Asfaw Y. Seroepidemiological investigation of bovine 
brucellosis in the extensive cattle production system of Tigray region of Ethiopia; 
Intern J Appl Res Vet Med, vol. 5, No 2, 2007 
 
30. Gomez M, Nieto J, Rosa G et al. Evaluation of serum test for diagnosis of 
human brucellosis in an area where the disease is endemic. Clinical and vaccine 
Immunology, p. 1031-1033, June 2008 
 
31. Chachra D, Saxena H, Kaur G et al. Comparative efficacy of Rose Bengal 
plate test, standard tube agglutination test and dot ELISA in immunological 
detection of Ab to Brucella abortus in sera. Journal of Bacteriology research, Vol. 
1(3), p. 030-033, June, 2009 
 
32.  Gerrit J, Viljoen, Lous H et al. Molecular diagnostic PCR handbook, 2006 
 
- 62 - 
 
33. Samad A, Awaz  K and Sarkate L. Diagnosis of bovine traumatic reticuloperitonitis 
I: strength of clinical signs in predicting correct diagnosis. J. of Appli. Anim.Res. 6: 13-
18, 1994 
 
34. Ilhan Z, Solmaz H, et al. Detection of Brucella melitensis DNA in the milk of 
sheep after abortion by PCR; Arch. Med. Vet. 40, N2, p. 141-146, 2008 
35. Mainar-Jaime R, Munoz P. Specificity dependence between serological tests 
for diagnostic bovine brucellosis in Brucella-free farms showing false positive 
serological reaction due to Yesinia enterocolitica O:9. Can Vet J, 46(10), 913-916, 
October 2005 
 
36. Ocampo-Sosa A, Garcia-Lobo J. Demonstration of IS711 transposition in 
Brucella ovis and Brucella pinnipedialis; BMC Microbiology, 8:17, 2008. 
 
37. Del Vecchio V, Wagner M, Eschenbrenner M, Horn T, Kraycer J, Estock F, 
Elzer P, and Mujer C. Brucella Proteomes--A Review. Vet. Microbiol. 90: 592-
603, 2002c 
 
38. Bardenstein S, Mandelboim M, Ficht T et al. Identification of the Brucella 
melitensis vaccine strain Rev 1 in animals and humans in Israel by PCR analysis of 
the PstI site polymorphism of its omp2 gene. Journal of clinical microbiology, p. 
1475-1480, April 2002. 
 
 
 
 
- 63 - 
 
 
 
 
 
 
 
 
 
 
    
                           APPENDICES     
 
   
 
 
 
 
 
 
 
 
 
Appendix 1: Positive result of the serum sample by RBT and CFT 
Number Sample RBT CFT Culture 
1 8 ++++ 1:360 Positive 
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 2 10 +++ 1:40 Positive 
3 11 ++ 1:10 Negative 
4 13 ++++ 1:360 Positive 
5 15 +++ Negative Positive 
6 20 +++ Negative Negative 
7 22 ++++ 1:160 Positive 
8 24 ++ 1:20 Negative 
9 26 ++ 1:10 Negative 
10 28 ++++ 1:80 Positive  
11 29 +++  1:40  Negative 
12 30 Negative 1:360 Positive 
13 34 ++++ 1:360 Positive 
14 37 Negative 1:360 Positive 
15 41 +++ 1:40 Negative 
16 43 +++ 1:40 Negative 
17 45 ++++ 1:320 Positive 
18 47 ++++ 1:180 Positive 
19 50 ++++ 1:20 Negative 
20 51 ++++ 1:360 Positive 
21 53 ++++ 1:160 Positive 
22 54 ++++ Negative  
23 55 Negative 1:80 Negative 
24 59 ++++ 1:40 Negative 
25 63 +++ 1:20 Negative 
26 64 ++++ 1:80 Negative 
27 72 +++  1:40 Negative 
28 74 Negative 1:360  Positive  
29 80 ++++ 1:180 Positive 
30 82 +++ 1:40 Negative 
31 83 ++++ Negative Negative 
32 84 ++++ 1:360 Positive 
33 88 ++ 1:20 Negative 
34 90 +++ 1:40 Negative 
35 91 +++ 1:40 Negative 
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36 92 +++ 1:40 Negative 
37 93 ++++ 1:360 Positive 
38 94 ++++ 1:180 Positive 
39 96 +++ 1:40  
40 98 +++ 1:40  
41 99 +++ 1:40  
42 105 ++++ 1:80 Positive 
43 107 +++ Negative  
44 108 +++ 1:40 Negative 
45 112 +++ Negative Negative 
46 114 +++ 1:40 Negative  
47 116 ++++ Negative  
48 120 +++  1:40   
49 126 ++++ 1:80 Positive 
50 128 ++++ Negative  
51 132 ++++ Negative  
52 134 Negative 1:80  
53 137 ++++ 1:80 Positive 
54 138 ++++ Negative  
55 140 ++++ 1:40 Negative 
56 141 ++++ 1:80 Positive 
57 143 ++++ Negative  
58 147 ++++ Negative  
59 149 Negative 1:160 Negative 
60 151 +++ 1:40 Negative 
61 152 +++ 1:40 Negative 
62 153 ++++ 1:80 Positive 
63 154 ++ 1:20 Negative 
64 155 +++ Negative  
65 156 +++ 1:40  
66 160 +++ Negative  
67 161 ++ 1:40  
68 162 ++++ 1:360 Positive 
69 163 ++++  1:360 Positive  
- 66 - 
 
70 165 Negative 1:40   
71 173 +++ 1:40  
72 174 +++ 1:20  
73 177 ++ 1:20 Positive 
74 178 +++ Negative  
75 179 +++ 1:40 Negative 
76 180 ++++ 1:80  
77 189 ++++ 1:360 Negative 
78 190 ++++ Negative  
79 192 ++++ 1:320 Positive 
80 196 ++++ 1:180 Positive 
81 189                  ++++ 1:360 Positive 
82 190 ++++ Negative  
83 192 ++++ 1:320 Positive 
84 196 ++++ 1:180 Positive 
85 200 Negative 1:80  
86 203 ++++ 1:160 Positive 
87 207 ++++ Negative  
88 210 ++++ Negative  
89 213 ++++  1:20  Negative  
90 215 ++ 1:10  
91 219 ++++ 1:320 Positive 
92 220 ++++ 1:40 Negative 
93 226 ++++ 1:40  
94 228 ++++ 1:360 Positive 
95 230 +++ 1:40 Negative 
96 231 ++++ 1:320 Positive 
97 232 ++++ 1:40  
98 234 Negative 1:80  
99 235 ++++ 1:80  
100 237 ++ 1:20 Negative  
101 238 ++++ 1:80  
102 240 +++ Negative  
103 241 ++++ 1:40  
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Appendix 2: The result o milk sample from seropositive animals by culture 
(Brucella melitensis agar) and PCR. 
 
Sample Culture PCR from Culture PCR from Milk 
Brucella 
group 
B. 
melitensis 
Brucella 
group 
B. 
melitensis 
B. 
abortus 
1 Positive Positive Positive Positive Positive Negative 
2 Positive Positive Positive Positive Positive Positive 
3 Negative   Positive Positive Positive 
104 242 ++++ 1:20  
105 244 ++++ 1:40   
106 263 ++++ 1:40  
107 270 ++ Negative  
108 279 ++ 1:40 Negative 
109 280 ++++ 1:80  
110 282 Negative 1:180 Negative 
112 285 ++++ 1:360  
113 287 ++ 1:20  
114 290 +++ 1:40  
115 295 +++ 1:40 Negative 
116 297 ++++ 1:360  
117 301 ++++ 1:40 Negative 
118 302 ++++ 1:40 Negative 
119 304 ++++ 1:80 Positive 
120 305 ++++  1:320  Positive  
121 306 ++++ 1:360 Positive 
122 307 ++ Negative  
123 308 ++++ 1:40 Negative 
12 311 ++++ 1:80 Negative 
125 312 +++ Negative  
126 314 ++ Negative  
127 315 ++++ 1:20  
128 316 +++ Negative  
129 317 ++++ 1:40 Negative 
130 324 ++++ 1:160 Positive 
131 325 ++++ Negative  
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4 Positive Positive Positive Positive Positive Negative 
5 Positive Positive Positive Positive Positive Negative 
6 Negative   Positive Negative Positive 
7 Positive Positive Positive Positive Positive Negative 
8 Negative   Positive Positive Negative 
9 Negative   Positive Positive Negative 
10 Positive Positive Positive Positive Positive Negative 
11 Negative   Positive Positive Negative 
12 Positive Positive Positive Positive Positive Negative 
13 Positive Positive Positive Positive Positive Negative 
14 Positive Positive Positive Positive Positive Negative 
15 Negative   Negative Negative Negative 
16 Negative   Negative Negative Negative 
17 Positive Positive Positive Positive Positive Negative 
18 Positive Positive Positive Positive Positive Negative 
19 Negative   Negative Negative Negative 
20 Positive Positive Positive Positive Positive Negative 
21 Positive Positive Positive Positive Positive Negative 
22 Negative   Negative Negative Negative 
23 Negative   Positive Negative Positive 
24 Negative   Positive Negative Positive 
26 Negative   Positive Negative Positive 
27 Positive Positive Positive Positive Positive Negative 
28 Positive Positive Positive Positive Positive Negative 
29 Negative   Positive Negative Positive 
30 Negative   Negative Negative Negative 
31 Positive Positive Positive Positive Positive Negative 
32 Negative   Positive Negative Positive 
33 Negative   Negative Negative Negative 
34 Negative   Negative Negative Negative 
35 Negative   Negative Negative Negative 
36 Positive Positive Positive Positive Positive Negative 
37 Positive Positive Positive Positive Positive Negative 
38 Positive Positive Positive Positive Positive Positive 
39 Negative   Negative Negative Negative 
40 Negative   Positive Negative Positive 
41 Negative   Negative Negative Positive 
42 Positive Positive Positive Positive Positive Negative 
43 Positive Positive Positive Positive Positive Positive 
44 Negative   Negative Negative Negative 
45 Negative   Positive Negative Positive 
46 Negative   Negative Negative Negative 
47 Positive Positive Positive Positive Positive Positive 
48 Positive Positive Positive Positive Positive Negative 
49 Positive Positive Positive Positive Positive Positive 
50 Negative   Negative Negative Negative 
51 Positive Positive Positive Positive Positive Negative 
52 Positive Positive Positive Positive Positive Negative 
53 Positive Positive Positive Positive Positive Negative 
54 Negative   Positive Negative Positive 
55 Negative   Positive Negative Positive 
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56 Positive Positive Positive Positive Positive Negative 
57 Positive Positive Positive Positive Positive Negative 
58 Positive Positive Positive Positive Positive Negative 
59 Negative   Positive Negative Positive 
60 Positive Positive Positive Positive Positive Negative 
61 Negative   Negative Negative Negative 
62 Positive Positive Positive Positive Positive Positive 
63 Negative   Positive Negative Positive 
64 Positive Positive Positive Positive Positive Negative 
65 Negative   Negative Negative Negative 
66 Positive Positive Positive Positive Positive Negative 
67 Negative   Positive Negative Positive 
68 Negative   Positive Negative Positive 
69 Negative   Negative Negative Negative 
70 Negative   Negative Negative Negative 
71 Positive Positive Positive Positive Positive Negative 
72 Positive Positive Positive Positive Positive Negative 
73 Negative   Positive Negative Positive 
74 Negative   Positive Negative Positive 
75 Negative   Positive Negative Positive 
75 Negative   Positive Negative Positive 
76 Positive Positive Positive Positive Positive Negative 
77 Positive Positive Positive Positive Positive Negative 
78 Negative   Positive Negative Positive 
79 Negative   Positive Negative Positive 
80 Negative   Positive Negative Positive 
                Appendix 3: Primer design 
 
For design of the internal primer pair, the Open read frame Brucella melitensis 
gene was downloaded Primer3 Output (http://frodo.wi.mit.edu/primer3). The 
primer sequence was selected with the following properties: 20-25 nucleotides 
starting with at least one G or C nucleotides at the 5’, terminated with GC at 
3’end. The GC content of ~ 50%. 
No mispriming library specified 
Using 1-based sequence positions 
OLIGO                     start  len      tm     gc%   any    3' seq  
LEFT PRIMER        253   20   59.94   45.00  2.00  0.00 
GAACCCAGAATACGGCAAAA 
RIGHT PRIMER       454   20   60.03   50.00  4.00  3.00 
GTCGTTTCTGCGTCAACAGA 
SEQUENCE SIZE: 1025 
INCLUDED REGION SIZE: 1025 
PRODUCT SIZE: 202, PAIR ANY COMPL: 7.00, PAIR 3' COMPL: 
1.00 
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    1 
AAGGCAAAAACGGCCTGCAATAAGCGGCATACCTTCGCGCGCCAGGGAGAACGTGAATG
A 
                                                                   
 
   61 
TAGTTCTAATACCCTTGAAGGAAAACTGTACGGACGACTATGCGTCATCAACGTTGGGT
A 
                                                                   
 
  121 
CCTCTTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGG
G 
                                                                   
 
  181 
CAATCCTGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCC
G 
                                                                   
 
  241 
AGGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTC
A 
                  >>>>>>>>>>>>>>>>>>>>                             
 
  301 
GTCTGCAAGAAAATACTATTGATGCTTCGCTTGCCGTCAACAATGCGGCGAACAGGATT
G 
                                                                   
 
  361 
CCATCGACAAGGAAGGCGATCCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAG
C 
                                                                   
 
  421 
AGAACAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAGCG
A 
                    <<<<<<<<<<<<<<<<<<<<                           
 
  481 
CAGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTCTGAACGTAGCGGAA
A 
                                                                   
 
  541 
ACATTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCCGCAGGT
C 
                                                                   
 
  601 
ATCAGATTGTGATCGGTGGTCAACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGT
T 
                                                                   
 
  661 
CAACGATATCGCATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTTATT
G 
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  721 
CCAATAACCAGGCAACATCGTGACAGATGCGGCTGATCATTTGACAATCTCCAGCGCGT
C 
                                                                   
 
  781 
TATTGTGTGGAGGGTTACAGCTGACTGATTGTGCAGGTGATGCATGCCGACGAAAGCAT
G 
                                                                   
 
  841 
TTCCCGATTAGTCCTAGTCGGAATAATGCCTGTGACCTCTAAACATCGATCAGTACACC
A 
                                                                   
 
  901 
TCCATCTGCAGCAACAGTCCTTCTACGGTATGACTGAAACTCACGGCCATACGGACTTG
G 
                                                                   
 
  961 
AACGCATTTAGCCTGGCCTCGTGGCTAACCATCCAGAATAACTCCATGTTATATCTGAA
A 
                                                                 
1021 TGTCG 
Sequence choose for primer design, red color primer 1, and blue – primer 2 
 
 
 
 
 
 
 
Name of 
primer 
Sequence Annelin
g 
tempera
ture 
Size Reference 
BM-
ORF1-
forward 
5’-
GAACCAGAATACGGCAAAA-
3’ 
 
52ºC 
 
202 
bp 
 
Our 
design 
BM-
ORF1-
reverse 
5’-
GTCGTTTCTGCGTCAACAGA
-3’ 
BM-
ORF2-
forwadr 
5’-
AGGGAGAACGTGAATGAT-
3’ 
 
59.5ºC 
 
195 
bp 
 
Our 
design 
BM-
ORF2-
reverse 
5’-
GCCGGTTGCAATGTTTATCT-
3’ 
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 Primer design 1: product size 202 bp 
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                 Primer design 2, product size 195 bp 
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Appendix 5: Complement Fixation Test picture 
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       Appendix 5: Brucella melitensis Biochemical test  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The stain, urea and oxidase 
test 
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Appendix 6: Alignment 
 
DNA analysis 
 
Sequenced Open read frame further were compare by BLAST with reference gene 
library strain of Brucella melitensis. In figure 4 shown that’s our isolate alignment 
with hemagglutinin and glycoprotein X precursor sequence Brucella melitensis of 
reference strain. In addition, our isolate was alignment with hypothetical protein for B. 
suis, putative cell wall surface protein of B. ovis,   cell wall protein AWA1 
precursor of B. canis 
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gb|AE008918.1|  Brucella melitensis 16M chromosome II, complete sequence 
Length=1177787 
 
 Features in this part of subject sequence: 
   hemagglutinin 
 
 Score = 1404 bits (760),  Expect = 0.0 
 Identities = 846/883 (95%), Gaps = 24/883 (2%) 
 Strand=Plus/Plus 
 
 
Query  5       CAAAAACGGCCTGCAATAAGCGGC-ATACC-TTCGCGCGCCAGGGA-
GAACGTGAATGAT  61 
               |||| |||| ||||| | |||||| ||||| ||||||| |||  || || 
|||||||||| 
Sbjct  755420  CAAATACGG-CTGCAGTCAGCGGCAATACCATTCGCGC-CCA--
GACGATCGTGAATGAT  755475 
 
Query  62      
AGTTCTAATACCCTTGAAGGAAAACTGTACGGACGACTATGCGTCATCAACGTTGGGTAC  121 
               |||||||||||||||||||||||||||| 
||||||||||||||||||||||||||||||| 
Sbjct  755476  AGTTCTAATACCCTTGAAGGAAAACTGT-
CGGACGACTATGCGTCATCAACGTTGGGTAC  755534 
 
Query  122     
CTCTTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGC  181 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  755535  
CTCTTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGC  755594 
 
Query  182     
AATCCTGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCCGA  241 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  755595  
AATCCTGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCCGA  755654 
 
Query  242     
GGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTCAG  301 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  755655  
GGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTCAG  755714 
 
Query  302     
TCTGCAAGAAAATACTATTGATGCTTCGCTTGCCGTCAACAATGCGGCGAACAGGATTGC  361 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  755715  
TCTGCAAGAAAATACTATTGATGCTTCGCTTGCCGTCAACAATGCGGCGAACAGGATTGC  755774 
 
Query  362     
CATCGACAAGGAAGGCGATCCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCA  421 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  755775  
CATCGACAAGGAAGGCGATCCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCA  755834 
 
Query  422     
GAACAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAGCGAC  481 
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|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  755835  
GAACAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAGCGAC  755894 
 
Query  482     
AGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTCTGAACGTAGCGGAAAA  541 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  755895  
AGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTCTGAACGTAGCGGAAAA  755954 
 
Query  542     
CATTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCCGCAGGTCA  601 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  755955  
CATTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCCGCAGGTCA  756014 
 
Query  602     
TCAGATTGTGATCGGTGGTCAACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGTTC  661 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  756015  
TCAGATTGTGATCGGTGGTCAACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGTTC  756074 
 
Query  662     
AACGATATCGCATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTTATTGC  721 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  756075  
AACGATATCGCATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTTATTGC  756134 
 
Query  722     CAATAACCAGGCAA-
CATCGTGACAGATGCGGCTGATCATTTGACAATCTCCAGCGCGTC  780 
               |||||||||||||| |||||| 
|||||||||||||||||||||||||||||||||||||| 
Sbjct  756135  
CAATAACCAGGCAAACATCGTTACAGATGCGGCTGATCATTTGACAATCTCCAGCGCGTC  756194 
 
Query  781     TATTG-TGTGGAGGGTTACAGCTGACTGATTG-TGCAGGT-
GATGCATGCCGACGAAAGC  837 
               ||||| |||||||||| ||| | ||| ||||| ||| ||| | || |||||| |||| 
|  
Sbjct  756195  TATTGGTGTGGAGGGT-ACACC-GAC-GATTGGTGC-GGTTGTTG-
ATGCCGTCGAAGG-  756248 
 
Query  838     ATGTTCCCGATTAGTCCTAGTCGGAATAATGCCTGTGACCTCT  880 
               | ||||  | || ||||| | |||| ||||||| ||||| ||| 
Sbjct  756249  AGGTTCG-G-TT-GTCCTCG-CGGA-TAATGCC-GTGACGTCT  756285 
 
 Alignment of the flock 1 Palestinian hemagglutinin gene 16M Brucella 
melitensis (Query), Sbjct (ATCC) 
 
gb|CP001489.1|  Brucella melitensis ATCC 23457 chromosome II, complete 
sequence 
Length=1185518 
 
 Features in this part of subject sequence: 
   Glycoprotein X precursor 
 
 Score = 1404 bits (760),  Expect = 0.0 
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 Identities = 846/883 (95%), Gaps = 24/883 (2%) 
 Strand=Plus/Minus 
 
Query  5       CAAAAACGGCCTGCAATAAGCGGC-ATACC-TTCGCGCGCCAGGGA-
GAACGTGAATGAT  61 
               |||| |||| ||||| | |||||| ||||| ||||||| |||  || || 
|||||||||| 
Sbjct  514620  CAAATACGG-CTGCAGTCAGCGGCAATACCATTCGCGC-CCA--
GACGATCGTGAATGAT  514565 
 
Query  62      
AGTTCTAATACCCTTGAAGGAAAACTGTACGGACGACTATGCGTCATCAACGTTGGGTAC  121 
               |||||||||||||||||||||||||||| 
||||||||||||||||||||||||||||||| 
Sbjct  514564  AGTTCTAATACCCTTGAAGGAAAACTGT-
CGGACGACTATGCGTCATCAACGTTGGGTAC  514506 
 
Query  122     
CTCTTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGC  181 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  514505  
CTCTTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGC  514446 
 
Query  182     
AATCCTGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCCGA  241 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  514445  
AATCCTGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCCGA  514386 
 
Query  242     
GGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTCAG  301 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  514385  
GGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTCAG  514326 
 
Query  302     
TCTGCAAGAAAATACTATTGATGCTTCGCTTGCCGTCAACAATGCGGCGAACAGGATTGC  361 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  514325  
TCTGCAAGAAAATACTATTGATGCTTCGCTTGCCGTCAACAATGCGGCGAACAGGATTGC  514266 
 
Query  362     
CATCGACAAGGAAGGCGATCCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCA  421 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  514265  
CATCGACAAGGAAGGCGATCCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCA  514206 
 
Query  422     
GAACAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAGCGAC  481 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  514205  
GAACAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAGCGAC  514146 
 
Query  482     
AGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTCTGAACGTAGCGGAAAA  541 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  514145  
AGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTCTGAACGTAGCGGAAAA  514086 
 
Query  542     
CATTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCCGCAGGTCA  601 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  514085  
CATTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCCGCAGGTCA  514026 
 
Query  602     
TCAGATTGTGATCGGTGGTCAACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGTTC  661 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  514025  
TCAGATTGTGATCGGTGGTCAACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGTTC  513966 
 
Query  662     
AACGATATCGCATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTTATTGC  721 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  513965  
AACGATATCGCATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTTATTGC  513906 
 
Query  722     CAATAACCAGGCAA-
CATCGTGACAGATGCGGCTGATCATTTGACAATCTCCAGCGCGTC  780 
               |||||||||||||| |||||| 
|||||||||||||||||||||||||||||||||||||| 
Sbjct  513905  
CAATAACCAGGCAAACATCGTTACAGATGCGGCTGATCATTTGACAATCTCCAGCGCGTC  513846 
 
Query  781     TATTG-TGTGGAGGGTTACAGCTGACTGATTG-TGCAGGT-
GATGCATGCCGACGAAAGC  837 
               ||||| |||||||||| ||| | ||| ||||| ||| ||| | || |||||| |||| 
|  
Sbjct  513845  TATTGGTGTGGAGGGT-ACACC-GAC-GATTGGTGC-GGTTGTTG-
ATGCCGTCGAAGG-  513792 
 
Query  838     ATGTTCCCGATTAGTCCTAGTCGGAATAATGCCTGTGACCTCT  880 
               | ||||  | || ||||| | |||| ||||||| ||||| ||| 
Sbjct  513791  AGGTTCG-G-TT-GTCCTCG-CGGA-TAATGCC-GTGACGTCT  513755 
 
Alignment Palestinian glycoprotein x precursor 16M Brucella melitensis (Query), 
Sbjct (ATCC) 
 
gb|CP000912.1|  Brucella suis ATCC 23445 chromosome II, complete sequence 
Length=1400844 
 
 Features in this part of subject sequence: 
   Hypothetical protein, conserved 
 
 Score = 1393 bits (754),  Expect = 0.0 
 Identities = 845/884 (95%), Gaps = 26/884 (2%) 
 Strand=Plus/Minus 
 
Query  5       CAAAAACGGCCTGCAATAAGCGGC-ATACC-TTCGCGCGCCAGGGA-
GAACGTGAATGAT  61 
               |||| |||| ||||| | |||||| ||||| ||||||| |||  || || 
|||||||||| 
Sbjct  535145  CAAATACGG-CTGCAGTCAGCGGCAATACCATTCGCGC-CCA--
GACGATCGTGAATGAT  535090 
 
- 82 - 
 
Query  62      
AGTTCTAATACCCTTGAAGGAAAACTGTACGGACGACTATGCGTCATCAACGTTGGGTAC  121 
               |||||||||||||||||||||||||||| 
||||||||||||||||||||||||||||||| 
Sbjct  535089  AGTTCTAATACCCTTGAAGGAAAACTGT-
CGGACGACTATGCGTCATCAACGTTGGGTAC  535031 
 
Query  122     
CTCTTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGC  181 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  535030  
CTCTTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGC  534971 
 
Query  182     
AATCCTGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCCGA  241 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534970  
AATCCTGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCCGA  534911 
 
Query  242     
GGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTCAG  301 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534910  
GGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTCAG  534851 
 
Query  302     
TCTGCAAGAAAATACTATTGATGCTTCGCTTGCCGTCAACAATGCGGCGAACAGGATTGC  361 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534850  
TCTGCAAGAAAATACTATTGATGCTTCGCTTGCCGTCAACAATGCGGCGAACAGGATTGC  534791 
 
Query  362     
CATCGACAAGGAAGGCGATCCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCA  421 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534790  
CATCGACAAGGAAGGCGATCCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCA  534731 
 
Query  422     
GAACAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAGCGAC  481 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534730  
GAACAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAGCGAC  534671 
 
Query  482     
AGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTCTGAACGTAGCGGAAAA  541 
               ||||||||||||||||||||||||||||||||||||||||| 
|||||||||||||||||| 
Sbjct  534670  
AGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAATCTGAACGTAGCGGAAAA  534611 
 
Query  542     
CATTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCCGCAGGTCA  601 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534610  
CATTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCCGCAGGTCA  534551 
 
Query  602     
TCAGATTGTGATCGGTGGTCAACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGTTC  661 
- 83 - 
 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534550  
TCAGATTGTGATCGGTGGTCAACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGTTC  534491 
 
Query  662     
AACGATATCGCATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTTATTGC  721 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534490  
AACGATATCGCATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTTATTGC  534431 
 
Query  722     CAATAACCAGGCAA-CATCG-
TGACAGATGCGGCTGATCATTTGACAATCTCCAGCGCGT  779 
               |||||||||||||| ||||| | 
||||||||||||||||||||||||||||||||||||| 
Sbjct  534430  CAATAACCAGGCAAACATCGGT-
ACAGATGCGGCTGATCATTTGACAATCTCCAGCGCGT  534372 
 
Query  780     CTATTG-TGTGGAGGGTTACAGCTGACTGATTG-TGCAGGT-
GATGCATGCCGACGAAAG  836 
               |||||| |||||||||| ||| | ||| ||||| ||| ||| | || |||||| |||| 
| 
Sbjct  534371  CTATTGGTGTGGAGGGT-ACACC-GAC-GATTGGTGC-GGTTGTTG-
ATGCCGTCGAAGG  534317 
 
Query  837     CATGTTCCCGATTAGTCCTAGTCGGAATAATGCCTGTGACCTCT  880 
                | ||||  | || ||||| | |||| ||||||| ||||| ||| 
Sbjct  534316  -AGGTTCG-G-TT-GTCCTTG-CGGA-TAATGCC-GTGACGTCT  534280 
 
               Alignment our isolate with hypothetical protein Brucella sius 
 
gb|CP000709.1|  Brucella ovis ATCC 25840 chromosome II, complete sequence 
Length=1164220 
 
 Features in this part of subject sequence: 
   putative cell wall surface protein 
 
 Score = 1399 bits (757),  Expect = 0.0 
 Identities = 846/884 (95%), Gaps = 26/884 (2%) 
 Strand=Plus/Minus 
Query  5       CAAAAACGGCCTGCAATAAGCGGC-ATACC-TTCGCGCGCCAGGGA-
GAACGTGAATGAT  61 
               |||| |||||| ||| | |||||| ||||| ||||||| |||  || || 
|||||||||| 
Sbjct  536302  CAAATACGGCC-GCAGTCAGCGGCAATACCATTCGCGC-CCA--
GACGATCGTGAATGAT  536247 
 
Query  62      
AGTTCTAATACCCTTGAAGGAAAACTGTACGGACGACTATGCGTCATCAACGTTGGGTAC  121 
               |||||||||||||||||||||||||||| 
||||||||||||||||||||||||||||||| 
Sbjct  536246  AGTTCTAATACCCTTGAAGGAAAACTGT-
CGGACGACTATGCGTCATCAACGTTGGGTAC  536188 
 
Query  122     
CTCTTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGC  181 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  536187  
CTCTTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGC  536128 
 
- 84 - 
 
Query  182     
AATCCTGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCCGA  241 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  536127  
AATCCTGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCCGA  536068 
 
Query  242     
GGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTCAG  301 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  536067  
GGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTCAG  536008 
Query  302     
TCTGCAAGAAAATACTATTGATGCTTCGCTTGCCGTCAACAATGCGGCGAACAGGATTGC  361 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  536007  
TCTGCAAGAAAATACTATTGATGCTTCGCTTGCCGTCAACAATGCGGCGAACAGGATTGC  535948 
 
Query  362     
CATCGACAAGGAAGGCGATCCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCA  421 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  535947  
CATCGACAAGGAAGGCGATCCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCA  535888 
 
Query  422     
GAACAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAGCGAC  481 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  535887  
GAACAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAGCGAC  535828 
 
Query  482     
AGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTCTGAACGTAGCGGAAAA  541 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  535827  
AGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTCTGAACGTAGCGGAAAA  535768 
 
Query  542     
CATTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCCGCAGGTCA  601 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  535767  
CATTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCCGCAGGTCA  535708 
 
Query  602     
TCAGATTGTGATCGGTGGTCAACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGTTC  661 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  535707  
TCAGATTGTGATCGGTGGTCAACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGTTC  535648 
 
Query  662     
AACGATATCGCATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTTATTGC  721 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  535647  
AACGATATCGCATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTTATTGC  535588 
 
Query  722     CAATAACCAGGCAA-CATCG-
TGACAGATGCGGCTGATCATTTGACAATCTCCAGCGCGT  779 
- 85 - 
 
               |||||||||||||| ||||| | 
||||||||||||||||||||||||||||||||||||| 
Sbjct  535587  CAATAACCAGGCAAACATCGGT-
ACAGATGCGGCTGATCATTTGACAATCTCCAGCGCGT  535529 
 
Query  780     CTATTG-TGTGGAGGGTTACAGCTGACTGATTG-TGCAGGT-
GATGCATGCCGACGAAAG  836 
               |||||| |||||||||| ||| | ||| ||||| ||| ||| | || |||||| |||| 
| 
Sbjct  535528  CTATTGGTGTGGAGGGT-ACACC-GAC-GATTGGTGC-GGTTGTTG-
ATGCCGTCGAAGG  535474 
 
Query  837     CATGTTCCCGATTAGTCCTAGTCGGAATAATGCCTGTGACCTCT  880 
                | ||||  | || ||||| | |||| ||||||| ||||| ||| 
Sbjct  535473  -AGGTTCG-G-TT-GTCCTTG-CGGA-TAATGCC-GTGACGTCT  535437 
 
Alignment our isolate with putative cell wall surface protein 
 protein Brucella ovis 
 
gb|CP000873.1|  Brucella canis ATCC 23365 chromosome II, complete sequence 
Length=1206800 
 
 Features in this part of subject sequence: 
   Cell wall protein AWA1 precursor 
 
 Score = 1038 bits (562),  Expect = 0.0 
 Identities = 604/623 (96%), Gaps = 8/623 (1%) 
 Strand=Plus/Minus 
 
Query  10      CAAA-ACGGCTGC-GTC-GCGGCAATACCATTCGCGCCGAGGAC-
AACGTGAATGATAGT  65 
               |||| |||||||| ||| |||||||||||||||||||| | ||| | 
||||||||||||| 
Sbjct  534533 CAAATACGGCTGCAGTCAGCGGCAATACCATTCGCGCCCA-
GACGATCGTGAATGATAGT  534475 
 
Query  66     
TCTAATACCCTTGAAGGGAAAACAGACGGACGACTATGCGTCATCAACGTTGGGTACCTC  125 
               ||||||||||||||| ||||||| | 
|||||||||||||||||||||||||||||||||| 
Sbjct 534474 TCTAATACCCTTGAA-GGAAAACTGTCGGACGACTATGCGTCATCAACGTTGGGTACCTC  
534416 
 
Query  126     
TTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGCAAT  185 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534415  
TTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGCAAT  534356 
 
Query  186     
CCTGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCCGAGGG  245 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534355  
CCTGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCCGAGGG  534296 
 
Query  246     
CATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTCAGTCT  305 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
- 86 - 
 
Sbjct  534295  
CATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTCAGTCT  534236 
 
Query  306     
GCAAGAAAATACTATTGATGCTTCGCTTGCCGTCAACAATGCGGCGAACAGGATTGCCAT  365 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534235  
GCAAGAAAATACTATTGATGCTTCGCTTGCCGTCAACAATGCGGCGAACAGGATTGCCAT  534176 
 
Query  366     
CGACAAGGAAGGCGATCCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCAGAA  425 
               |||||||||| 
||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534175  
CGACAAGGAAAGCGATCCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCAGAA  534116 
 
Query  426     
CAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAGCGACAGA  485 
               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534115  
CAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAGCGACAGA  534056 
 
Query  486     
AGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTCTGAACGTAACGGAAAAACA  545 
               ||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| 
|| 
Sbjct  534055  AGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTCTGAACGTAGCGGAAAA-
CA  533997 
 
Query  546     
TTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCAACATGTCATC  605 
               |||||||||||||||||||||||||||||||||||||||||||||||||  || 
|||||| 
Sbjct  533996  
TTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCCGCAGGTCATC  533937 
 
Query  606     CAGATAGTGATCGGTGGACAACT  628 
                |||| ||||||||||| ||||| 
Sbjct  533936  -AGATTGTGATCGGTGGTCAACT  533915 
 
Alignment our isolate with cell wall protein AWA1 precursor 
 protein Brucella canis 
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Alignment 7: DNA sequencing 
Sequence Brucella melitensis from farm 1 - forward 
ORF F3-1 F 
AAGGCAAAAACGGCCTGCAATAAGCGGCATACCTTCGCGCGCCAGGG
AGAACGTGAATGATAGTTCTAATACCCTTGAAGGAAAACTGTACGGAC
GACTATGCGTCATCAACGTTGGGTACCTCTTCCTTAACCTTTGGGACTC
CTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGCAATCCTGGCAG
AAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCC
GAGGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGC
TGGGGCAAGCCTCAGTCTGCAAGAAAATACTATTGATGCTTCGCTTGC
CGTCAACAATGCGGCGAACAGGATTGCCATCGACAAGGAAGGCGATC
CGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCAGAACAAAG
AGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAA
GCGACAGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGT
CTGAACGTAGCGGAAAACATTGTTTCCAGTTCTGCAACCGGTAACCAG
ACCGTTGGTGCCGCAGGCGCCGCAGGTCATCAGATTGTGATCGGTGGT
CAACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGTTCAACGATA
TCGCATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTT
ATTGCCAATAACCAGGCAACATCGTGACAGATGCGGCTGATCATTTGA
CAATCTCCAGCGCGTCTATTGTGTGGAGGGTTACAGCTGACTGATTGT
GCAGGTGATGCATGCCGACGAAAGCATGTTCCCGATTAGTCCTAGTCG
GAATAATGCCTGTGACCTCTAAACATCGATCAGTACACCATCCATCTG
CAGCAACAGTCCTTCTACGGTATGACTGAAACTCACGGCCATACGGAC
TTGGAACGCATTTAGCCTGGCCTCGTGGCTAACCATCCAGAATAACTC
CATGTTATATCTGAAATGTCG 
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          Sequence Brucella melitensis from farm 2 - forward 
ORF F3 – F 
CCTGGCCAAAAAACGGCTGCGTCGCGGCAATACCTTCGCGCCGAGGG
AAAACGTGAATGATAGTTCTAATACCCTTGAAGGAAAACAGTCGGAC
GACTATGCGTCATCAACGTTGGGTACCTCTTCCTTAACCTTTGGGACTC
CTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGCAATCCTGGCAG
AAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCC
GAGGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCGC
TGGGGCAAGCCTCAGTCTGCAAGAAAATACTATTGATGCTTCGCTTGC
CGTCAACAATGCGGCGAACAGGATTGCCATCGACAAGGAAGGCGATC
CGACTTTCCAAGGCTCGTCCTTATTACCAATCTGCAGCAGAACAAAGA
GGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCAAG
CGACAGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTC
TGAACGTAGCGGAAAACATTGTTTCCAGTTCTGCAACCGGTAACCAGA
CCGTTGGTGCCGCAGGCGCCGCAGGTCATCAGATTGTGATCGGTGGTC
AACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGTTCAACGATAT
CGCATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTTA
TTGCCAATAACCAGGCAAACATCGTTACAGATGCGGCTTGATCATTTG
ACAATCTCCAGCGCGTCTATTTGGTGTGGAGGGTACACCGACGATTGG
TGCGGTTGTTGATGCCGTCGAAGGATGTTTCGGTGTCCCTCGCCGGAT
AATGCCCGGTGACGTCCTCAGGCCGGTAAGGTAACATCCACATCCCGC
ATGCAAGTCCTGAAGGATTGATCGACCTCCGCAAATCGGCTTGATGCA
TCAGCCTGGCCCCCTGGCTACCATTCAGATTAAACCTGATTCTGAATAT
TTGCGGCATCGATGCT 
 
 
 
 
 
 
 
 
Sequence Brucella melitensis from vaccine strain REV 1 
ORF REV 1 – 1 F 
- 89 - 
 
TCCTGGGTCCAAAACGGCTGCGTCGCGGCAATACCATTCGCGCCGAGG
ACAACGTGAATGATAGTTCTAATACCCTTGAAGGGAAAACAGACGGA
CGACTATGCGTCATCAACGTTGGGTACCTCTTCCTTAACCTTTGGGACT
CCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGCAATCCTGGCA
GAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTC
CGAGGGCATAATAGGAACCCAGAATACGGCAAAACAAGAGGTGGCCG
CTGGGGCAAGCCTCAGTCTGCAAGAAAATACTATTGATGCTTCGCTTG
CCGTCAACAATGCGGCGAACAGGATTGCCATCGACAAGGAAGGCGAT
CCGACTTTCCAAGGCTCGGTCCTTATTACCAATCTGCAGCAGAACAAA
GAGGGCTCTGTTGACGCAGAAACGACAGAGTCGGGTATATTGGCGCA
AGCGACAGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAG
TCTGAACGTAACGGAAAAACATTGTTTCCAGTTCTGCAACCGGTAACC
AGACCGTTGGTGCCGCAGGCGCAACATGTCATCCAGATAGTGATCGGT
GGACAACTTCGTGGGCGATGGGAAAACCAACACAAAACGCGCGGTTT
AGTGGTTTG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sequence Brucella melitensis from farm 1 - reverse 
ORF F3 – 1R 
ATCTTGGTACGGAATTTGTTACAAAAGTGTAATCCTTGCCACTGCAGG
AGAGGGGCTAGGGCATTGAGTGTCCCCCCAATCGACTGATGGACGAA
AGAGCCATAGGCCGCCATGATCATAGGCTGATGAATGGTATGGAAACT
ATCTTCGTTATCGCGTACATACGCTCCGTCAAGACCGGTATTTGATGAA
GTGGGATGCTCTTGAGCACCAGTTCCAATATTGGCAGTGACGGAATTG
- 90 - 
 
CTCTCGACCACCAGTTCATTGCGGCTCTGGGTGCCGCTGGCTGAGGCG
CTCTGCACATTGTCGGTTACCGAAAAGCTGGATTCCTCCTGTTTAACGT
TGGCATTAAAAAACGGTAGCGTTATGGGAGCCCTACTGCTGATTCCTG
GGAATCCTGCGACCGCATCGGTCAACGAAGCAATGACCGACGATCCA
GCATCACCCACCTGAACGTTGGCAATACCGGCCGAACCGGCGACACTG
TTTCCGCCAAGTCCGGCTACATGATCCGCCTTGCCGTCCTCATAATGCA
CTTGTCCAAGCAGATTAGTAGCGTCGCTACCAATCGCAGTCGCCTGCT
GCGTGTTGTTCTCGACGGTTAATTTGGCTCCAGATATGTCGCTACCAAC
CTTGTTGTCGCCGTAGACACCAACCACCGACGCCGCATTGTTGGCGGG
AAATGTCACTGCTATAGTTTTGCCTGGTAGGCTGGGTAAGCATATTAC
CATGCCTTAACCCCGAAAGGCCGACTATCATGGGGTAGTCCTGGTCAG
TTCGGTCCCGACCTGTCCGCACACCCTAGTGCTGATCCCCAGCGGTTTA
GGGTTATTGGGCGTTCCAGGGGCCACCTGGCTGGGCTGGAGGCTGTTG
CCCAACGCCCAGTGCGGAATATACTTGGTTCCCCCAGAAAGCACAAGG
GGGTCCCCTATACTCGAAGATCACCCTGTTCCTTTCGGCTTTTACCGGC
ACAGTGGCGAACCCACCGTGGACCCACTATTTTGTCCGGGTCTGCCCC
CCCGCCATCTATTCCAGAAAAAAAACAACCAGTATATTAATCTCATGA
GTGATGGGT 
 
 
 
 
 
 
 
Sequence Brucella melitensis from farm 2 - reverse 
ORF F3 – 2 R 
ACATTCTGGTACGGATTCCGTACCATTTTGGTAATCCTTGCATGCAGGC
AGGAAAAAGAGGGCATTGACTCTCCCCCCAATCGACTGATCGAAAGA
TAAGGCCATAGGCCGCCATGATCATAGGCTGATGAATGGTATGGAAAC
TATCTTCGTTATCGCGTACATACGCTCCGTCAAGACCGGTATTTGATGA
AGTGGGATGCTCTTGAGCACCAGTTCCAATATTGGCAGTGACGGAATT
GCTCTCGACCACCAGTTCATTGCGGCTCTGGGTGCCGCTGGCTGAGGC
GCTCTGCACATTGTCGGTTACCGAAAAGCTGGATTCCTCCTGTTTAACG
TTGGCATTAAAAAACGGTAGCGTTATGGGAGCCCTACTGCTGATTCCT
GGGAATCCTGCGACCGCATCGGTCAACGAAGCAATGACCGACGATCC
- 91 - 
 
AGCATCACCCACCTGAACGTTGGCAATACCGGCCGAACCGGCGACACT
GTTTCCGCCAAGTCCGGCTACATGATCCGCCTTGCCGTCCTCATAATGC
ACTTGTCCAAGCAGATTAGTAGCGTCGCTACCAATCGCAGTCGCCTGC
TGCGTGTTGTTCTCGACGGTTAATTTGGCTCCAGATATGTCGCTACCAA
CCTTGTTGTCGCCGTAGACACCAACCACCGACGCCGCATTGTTGGCGG
AAATATCACTGCTATAGTTTGCCTGTAAGCTGGTAAGCATAGCACCTG
CCTTAGCCCGAAGGCCGCTATCATGGGTAGTCTCGTCGTTCGGCCCGC
CCGTCAGCAACCCAGTGCTATCCCCAGCGGTTTAGGTTATTGGCGTCC
AGGGCCCAACTGCTGGCTGGCGCTGTTGCCAACGCCAGTGCGTAATCT
TGTTCCCCGAAACATCAACGGTACCATTCATCGAGGATACTGTCTCTC
AGCTTACGGACATGGCACCACTGAACATTTAGCGTGGCTCGCCGCATA
TTCCGAAACAGTTAATTCGATGTTAGCCAGGGCAGCTGGTAGGACTAT
CCAAGGCCGCGA 
 
 
 
 
 
 
 
 
Sequence Brucella melitensis REV 1 strain - reverse 
ORF REV1 – 1R 
AGTGTTCGCCGGTGACGCATTGGGTAAATGAGTTATCCTTGCCATGCA
GGGAGGGAGCAGGGCATTGATTGTTCCCCCAATCGACTGAGCGCCAA
AAAGGCCATAGGCCGCCATGATCATAGGCTGATGAATGGTATGGAAA
CTATCTTCGTTATCGCGTACATACGCTCCGTCAAGACCGGTATTTGATG
AAGTGGGATGCTCTTGAGCACAGTTCCAATATTGGCAGTGACGGAATT
GCTCTCGACCACCAGTTCATTGCGGCTCTGGGTGCCGCTGGCTGAGGC
GCTCTGCACATTGTCGGTTACCGAAAAGCTGGATTCCTCCTGTTTAACG
TTGGCATTAAAAAACGGTAGCGTTATGGGAGCCCTACTGCTGATTCCT
GGGAATCCTGCGACCGCATCGGTCAACGAAGCAATGACCGACGATCC
AGCATCACCCACCTGAACGTTGGCAATACCGGCCGAACCGGCGACACT
GTTTCCGCCAAGTCCGGCTACATGATCCGCCTTGCCGTCCTCATAATGC
ACTTGTCCAAGCAGATTAGTAGCGTCGCTACCAATCGCAGTCGCCTGC
TGCGTGTTGTTCTCGACGGTTAATTTGGCTCCAGATATGTCGCTACCAA
- 92 - 
 
CCTTGTTGTCGCCGTAGACACCAACCACCGACGCCGCATTGTTGGCGG
AAATATCACTGCTATAGTTTGCCTGTAAGCTGGTAAGCATAGCACCTG
CCTTAGCCCCGAAGGCCGCTATCATGGGTAGTCTCGTCGTTCGGCCCG
CCCGTCAGCAACCCAGTGCTATCCCAACGGTAAGGTTATTGGCGTCCA
GGTCAACTGCTGGCTGGCGCTGTTGCCAAACGCCAGTGCGAAAATCCT
TGGTACCCCGAAACATCAACGTACAATCAATCGCACGATACATGTTCT
TTTCGCGTTTGACTGAACAATGCAAGCGACTTGAGCCAATTACCTTGC
CGGCGCAACTTCAGGATACCAGTATCTGATGGTTAAGCCAAGGGCCAG
CCGTATGAGCTGATCCATAAG 
 
 
